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ABSTRACT OF DISSERTATION 
 
 
 
 
REGULATION OF UV-PROTECTIVE PATHWAYS DOWNSTREAM OF THE 
MELANOCORTIN 1 RECEPTOR IN MELANOCYTES 
 
Malignant cutaneous melanoma is the deadliest form of skin cancer, and a majority 
of melanoma diagnoses are a result of exposure to ultraviolet (UV) radiation. UV 
radiation causes DNA damage, which if not repaired correctly via nucleotide 
excision repair (NER) can result in mutations and melanomagenesis. The 
melanocortin 1 receptor (MC1R) is a Gs protein coupled receptor located on 
melanocyte plasma membranes and is involved in protecting the skin from UV 
induced damage. MC1R signaling results in the activation of two protective 
pathways: 1) induction of eumelanin synthesis downstream of micropthalmia-
associated transcription factor (MITF) and 2) acceleration of NER downstream of 
ataxia telangiectaseia mutated and Rad3 related (ATR). MC1R signaling, 
however, also promotes melanocyte proliferation, therefore, the activation of the 
MC1R pathway must be regulated. The overall hypothesis of this dissertation is 
that the pathways downstream of MC1R can be manipulated to protect against UV 
induced damage.  
 
Chapter 2 investigates the regulation of the MC1R neutral antagonist human β-
defensin 3 (βD3). UV damage did not induce βD3 mRNA expression in ex vivo 
human skin explants. The induction of βD3 expression instead correlated with 
inflammatory cytokines including TNFα. 
 
Chapter 3 investigates the interdependence and cross talk between the two 
protective pathways downstream of MC1R. We directly tested the effect of MITF 
on the acceleration of NER and the effect of ATR on the induction of eumelanin 
synthesis following MC1R activation. MITF was not required for the acceleration 
of NER as mediated by ATR, however, the induction of transcription of enzymes 
involved in eumelanin synthesis was dependent upon ATR kinase activity. 
 
Finally, Chapter 4 investigates the mechanism by which MC1R promoted 
proliferation and whether the two UV protective pathways downstream of MC1R 
could be selectively activated without the risk of melanocyte proliferation. MC1R 
signaling resulted in activation of the mechanistic target of rapamycin complex 1 
(mTORC1), a major regulator of cell growth and proliferation. Inhibition of 
mTORC1 signaling via rapamycin prevented MC1R induced proliferation in vitro.  
Rapamycin, however, did not prevent MC1R induced eumelanin synthesis or the 
acceleration of NER in vitro or in vivo suggesting it is possible to selectively activate 
the beneficial signaling pathways without the risk of melanocyte proliferation. 
 
The results of this dissertation suggest that MC1R signaling could be augmented 
in individuals to prevent UV induced damage. 
 
KEYWORDS: Melanocortin 1 Receptor (MC1R), β-Defensin 3 (βD3), 
Micropthalmia-Associated Transcription Factor (MITF), Ataxia Telangiectasia 
Mutated and Rad3 Related Protein (ATR), Mechanistic Target of Rapamycin 
(mTOR) 
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________________________________________________________________ 
 
Chapter 1: Introduction 
 
________________________________________________________________ 
 
1.1 Melanoma Introduction 
 
Malignant cutaneous melanoma is an aggressive form of skin cancer that is 
predicted to affect greater than 76,000 individuals in the United States in 2016 
(Howlander et al., 2015). It results from the uncontrolled proliferation of 
melanocytes located in the epidermal/dermal junction of the skin. There are two 
additional main categories of skin cancer, basal cell and squamous cell carcinoma, 
resulting from proliferation of epidermal basal cells or squamous keratinocytes 
respectively. 
 
Although cutaneous melanoma is only responsible for a small fraction of the total 
cases of skin cancer, because of its aggressive metastatic nature, it causes over 
90% of skin cancer related deaths (Howlander et al., 2015). Long-term prognosis 
correlates strongly with the stage of disease, and following metastasis, survival 
rates markedly decline. If diagnosed while in the early stages, surgical resection is 
associated with a nearly 100% five-year survival rate (Howlander et al., 2015; 
Schadendorf et al., 2015). If the the disease is not diagnosed early, however, it 
has a tendency to metastasize via both hematogenous and lymphatic routes. 
Although there has been great progress in treating melanoma utilizing both 
targeted molecular and immunotherapies, metastatic melanoma has a tendency 
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to recur. In general, the five-year survival rate for late stage metastatic melanoma 
is below	20% (Howlander et al., 2015). Early identification and treatment in addition 
to prevention are therefore essential clinical tools to minimize mortality. 	
 
Melanoma is concerning not only because of its aggressive nature, but also 
because its incidence rate has been steadily rising faster than any other cancer 
throughout the past century (Linos et al., 2009). In the early 1900’s the lifetime risk 
of developing melanoma in the United States was 1 in 1,500, while in 2002, the 
lifetime risk had risen to 1 in 62 (Rigel, 2002) (Figure 1.1)1. The incidence rate has 
continued to rise since 2002, and for the next decade it increased 1.8% per year, 
such that 21.3 per 100,000 individuals were diagnosed with melanoma between 
2007 and 2011 (Surveillance, Epidemiology, and End Results April 2014).  
 
The rise in melanoma incidence appears to be multifactorial resulting from 
environmental and cultural factors in addition to medical advancements. A 
component of the increase is believed to be due to enhanced awareness and 
improvements in diagnosis in addition to increased life expectancy (Balducci & 
Beghe, 2001). Melanoma incidence increases with advanced age, therefore, as 
life expectancy increases, melanoma rates would be predicted to increase as well. 
Although it can affect patients of any age, the average age at diagnosis and death 
is 62 and 69 years respectively (Surveillance, Epidemiology, and End Results 
February 2016). Many studies explain that one of the most important factors in the 
rise in incidence is an increase in exposure to ultraviolet (UV) radiation, either solar  
																																																						
1 All drawings, figures, and data are my original work unless otherwise stated. 
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Figure 1.1 Lifetime Risk of Developing Melanoma 
The lifetime risk of developing melanoma has risen over the past century 
from 1/1500 in 1900 to 1/52 in 2011.  
(Adapted from Wolf Horrell et al., 2015) 
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or artificial. Cutaneous melanoma has a high association with exposure to UV 
radiation (further discussed below) and is traditionally found on sun exposed 
surfaces (Rigel and Carucci, 2000). The popularization of a tanned physique in 
Western cultures beginning in the early 1900’s has led to an increase in intentional 
exposure to UV. Behavior modification has proved useful in decreasing incidence 
rates in other cancers, for example smoking cessation has led to a reduction in 
lung cancer incidence (Henly et al., 2010). Many individuals, however, believe they 
look better, feel healthier, and are happier with tanned skin (Balk et al., 2013). 
Minimizing UV exposure, therefore, has proved difficult suggesting the need to 
enhance innate protective mechanisms in order to prevent UV induced skin 
cancer. 
 
1.2 Ultraviolet Radiation 
 
Ultraviolet radiation is believed to be the main extrinsic risk factor associated with 
development of melanoma, with one study reporting over 80% of melanoma 
diagnoses being related to UV exposure (Parkin et al., 2011). Exposure to UV 
radiation correlates not only with the risk for developing melanoma (Armstrong & 
Kricker, 2001) but also with mortality rates (Boniol et al., 2005). The UV spectrum 
is divided into three wavelengths: UVA (320-400 nm), UVB (290-320 nm), and 
UVC (200-290 nm). As the wavelengths increase in energy (UVC>UVB>UVA), 
they penetrate less deeply into the skin and can cause greater direct cellular 
damage when absorbed. Although UVC can cause the greatest degree of cellular 
damage, a majority of UVC radiation is absorbed by ozone in the atmosphere and 
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is therefore not a major contributor to development of melanoma. The remaining 
UV radiation associated with ambient sunlight is approximately 90% UVA and 10% 
UVB.  
 
Unlike UVC, both UVA and UVB radiation are associated with the pathogenesis of 
melanoma due to distinct yet overlapping mechanisms (Gilchrest et al., 1999). 
UVB radiation is directly absorbed by nucleobases in DNA to produce the two 
major categories of bipyrimidine dimers: cyclobutadipyridime dimers (CPDs) and 
pyrimidine (6-4) pyrimidone photoproducts (6,4 PPs) (Sage, 1993; Dumaz et al., 
1997; Tadokoro et al., 2003; Markovitsi et al., 2009). Both are formed via a 
cycloaddition reaction: CPDs between the C5 and C6 double bond of two adjacent 
pyrmidines and 6,4 PPs between the C5 and C6 double bond of the 5’-base and 
the C4 carbonyl on the 3’-pyrmidine (the Paterno-Buchi reaction) (Cadet et al., 
2012). 6,4 PPs have the potential to further absorb UV radiation around 320 nm to 
photoisomerize into a third category of photoproducts: the Dewar isomer (Taylor 
and Cohrs, 1987; Matsunaga et al., 1991) (Figure 1.2). UVA radiation can also 
promote the formation of CPDs (Freeman et al., 1989), however, the mechanism 
is not as well characterized as UVB induced photoproducts. It is hypothesized that 
a combination of direct UVA photon absorption by DNA (Sutherland et al., 1981) 
in addition to photosensitization (Bosca et al., 2006) may contribute to UVA 
induced CPDs (Cadet et al., 2012). Photosensitization results from the excitation 
of endogenous chromophores, including melanin, and the subsequent 
redistribution of energy to DNA leading to the formation of CPDs (Bosco et al. 
2006; Premi et al. 2015).  
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Figure 1.2 UV Induced Thymine Dimer Photoproducts 
UVB absorption by DNA results in the formation of cyclobutadipyrimidine 
dimers (CPDs) and pyrimidine (6,4) pyrimidine photoproducts (6,4 PPs). 
6,4 PPs can further isomerize to Dewar valence isomers. UVA can also 
cause the formation of CPDs following direct absorption and 
photosensitization. 
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In addition to promoting the formation of bipyrmidine photoproducts, both UVA and 
UVB can cause oxidative damage to DNA (Cadet et al., 2015). UVA radiation is 
classically associated with an increase in free radicals and oxidative damage. 
Oxidative damage from UVA radiation can result either directly from 
photosensitization or indirectly via the generation of reactive oxygen and reactive 
nitrogen species due to activation of biological processes. Photosensitization can 
lead to the formation of charged radicals that react with oxygen producing 
superoxide promoting the oxidative signaling pathways (Cadet et al., 2015). 
Oxidation of guanine to 8-oxo-7,8-dihydroguanine is a marker of oxidative damage 
following UV radiation (Mouret et al., 2006) (Figure 1.3). UVB radiation is also 
capable of generating oxidative photoproducts, however, the mechanism by which 
UVB contributes to these photoproducts is still undetermined (Wei et al., 1998; 
Pelle et al., 2003).  
 
The formation of photoproducts following UV radiation can result in mutations if the 
lesions are not recognized and repaired correctly. CPDs have a greater degree of 
mutagenicity and are believed to be the major contributor to the generation of two 
of the UV signature mutations (You Y et al., 2001): cytosine à thymine base 
substitution and cytosine-cytosine à thymine – thymine tandem base substitution 
(Brash et al., 1991). 6,4 PPs are repaired more efficiently than CPDs, and therefore 
are only minor contributors to UV induced mutations (Ikehata and Ono, 2011). One 
of the mechanisms by which substitution mutations occurs is deamination of a 
cytosine to uracil in a CPD followed by translesional DNA synthesis (Tessman et 
al., 1992; Barak et al., 1995). Translesional DNA synthesis allows the cell to 
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Figure 1.3. UV Induced Oxidative DNA Photoproducts 
UVA can cause formation of 8-oxo-7,8-dihydroguanine following 
photosensitization or generation of reactive radical species. Exposure to 
UVB can also cause the formation of 8-oxo-7,8-dihydroguanine, 
however, the mechanism is less clear.  
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bypass a stalled replication fork resulting from helix distorting lesions. DNA 
polymerase η is specific for error-free translesionsal DNA synthesis opposite 
CPDs (Johnson et al., 1999; Masutani et al., 1999; Masutani  et al., 2000). If a 
cytosine has been deaminated to a uracil in a CPD, DNA polymerase η will pair 
the uracil with an adenine instead of guanine resulting in a mutation. A third UV 
signature mutation, a guanine à thymine transversion, occurs following oxidative 
damage (Ikehata and Ono, 2011) and the base pairing of 8-oxo-7,8-
dihydroguanine with adenine rather than cytosine. The presence of UV signature 
mutations in genes such as p53 in skin cancer contributed to our understanding of 
the importance of UV in the pathogenesis of melanoma (Brash et al., 1991). 
 
1.2.1 Nucleotide Excision Repair 
 
Nucleotide excision repair (NER) is the major genome maintenance pathway by 
which cells remove bulky DNA lesions that distort the DNA double helical structure 
including the UV induced photoproducts 6,4 PPs and CPDs. The NER pathway 
involves the coordinated action of multiple factors that recognize, excise, and 
repair damaged nucleotides (Figure 1.4).  
 
There are two categories of NER - global genome NER (GG-NER) and 
transcription coupled NER (TC-NER) which differ in their initiation mechanism. 
GG-NER scans the entire genome for bulky lesions while TC-NER recognizes 
DNA damage in transcribed regions of the genome after RNA polymerase has 
stalled allowing for repair of the damaged genome without disruption of 
transcription (Mellon et al., 1987; Mu & Sancar, 1997; Sugasawa et al., 1998;  
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Figure 1.4 NER Overview 
Nucleotide excision repair (NER) is the major mechanism by which cells 
remove bulky DNA lesions such as UV photoproducts. NER is 
accomplished through the coordinated action of proteins to (1) recognize 
DNA damage, (2) access and unwind the DNA in the region of the lesion, 
(3) incise and remove the damage, and (4) repair the gap with a high 
degree of fidelity using the undamaged strand as a template. In GG-NER, 
XPC and HR23B heterodimerize and scan the genome for helical 
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	 	distortions. In TC-NER, CSA and CSB are recruited to sites where RNA 
polymerase II has stalled due to helical distortions.  The 3’-5’ and 5’-3’ 
helicases XPB and XPD respectively unwind approximately 20-30 
nucleotides surrounding the DNA lesion creating two unprotected single 
strand sequences. Replication protein A and XPA are recruited to 
stabilize the open DNA conformation. ERCC1-XPF and XPG remove the 
damaged base 5’ and 3’ to the damaged base respectively. Polymerase 
δ and ε replace the gap.  
Abbreviations: CSA – Cockayne syndrome A; CSB – Cockayne 
syndrome B; TFIIH – transcription factor II human; RNAPII – RNA 
polymerase II; RPA – replication protein A; XP – xeroderma 
pigmentosum complementation group  
(Adapted from Wolf Horrell et al., 2015) 
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Sugasawa et al., 2001; Fousteri et al., 2006). In GG-NER, xeroderma 
pigmentosum complementation (XP) group C and HR23B heterodimerize and 
scan the genome for helical distortions (Sugasawa et al., 1998; Sugasawa et al., 
2001). In contrast, TC-NER is mediated by Cockayne syndrome A (CSA) and 
Cockayne syndrome B (CSB) proteins. CSA and CSB are recruited to sites where 
RNA polymerase II has stalled due to helical distortions (Mellon et al., 1987; 
Venema et al., 1991; Donahue et al., 1994; Mu and Sancar, 1997; Kamiuchi et al., 
2002). After damage recognition, transcription factor II human (TFIIH), a 
multiprotein complex composed of nine proteins, is recruited. TFIIH contains the 
3’-5’ and 5’-3’ helicases XPB and XPD respectively (Gerard et al., 1991). The 
helicases unwind approximately 20-30 nucleotides surrounding the DNA lesion 
creating two unprotected single strand sequences. Replication protein A (RPA) 
and XPA are recruited to stabilize the open DNA conformation (Tapias et al., 2004; 
Park and Choi, 2006) followed by the endonucleases excision repair cross-
complementation group 1 (ERCC1)-XPF and XPG which remove the damaged 
base (Mu and Sancar, 1997; Houtsmuller et al., 1999). Polymerase δ and ε in 
combination with proliferating cell nuclear antigen replace the gap using the 
undamaged complementary strand for fidelity (Shivji et al., 1995; Cleaver, 2005; 
Shah and He, 2015).  
 
The importance of DNA repair in preventing melanoma is evident in individuals 
diagnosed with xeroderma pigmentosum (XP) (Li et al., 2006; Paszkowska-Szczur 
et al., 2013) who have defective NER due to mutations in one of 8 factors 
associated with NER (Cleaver, 1968). These individuals are highly sensitive to UV 
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radiation and experience UV induced skin deformities early in life including 
epidermal thinning, telangiectasias, and altered pigmentation. In addition, they 
have an increased prevalence of skin malignancies (Eugene and Joshi, 2006) with 
a large number of UV induced mutations in oncogenes and tumor suppressors 
(D’Errico et al., 2000).  Individuals diagnosed with XP have over 1000 fold 
increased risk of development of skin cancer and are often diagnosed with 
melanoma in the second decade (on average over 40 years before the general 
public) (Bradford et al. 2011).  
 
1.3 Pigmentation 
 
One of the major innate defense mechanisms to protect against UV induced DNA 
damage is a high degree of skin pigmentation. Pigment is synthesized by 
melanocytes and transferred to keratinocytes in the epidermis where it 
accumulates. There are two major types of pigment present in the skin: eumelanin 
and pheomelanin. Eumelanin is a dark insoluble polymer that absorbs UV light 
(Kaidbey et al., 1979; Scherer and Kumar, 2010) and oxidants (Hoogduijn et al., 
2004), protecting DNA from their damaging effects. In contrast, pheomelanin is a 
soluble sulfated red/yellow polymer containing cysteine, which is much less 
efficient at blocking penetration of UV radiation and can promote UV-induced 
cellular damage by contributing to free radical and oxidative injury (Thody et al., 
1991; Mitra et al., 2012). The degree of skin pigmentation depends on the type 
and amount of melanin produced in addition to its cellular distribution rather than 
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number of melanocytes present in the skin (Rees, 2003; Dessinioti et al., 2011; 
D'Orazio et al., 2013).  
 
Synthesis of both eumelanin and pheomelanin begins with the conversion of 
tyrosine to L-3,4-dihydroxyphenylalanine (DOPA) and then to DOPAquinone via 
the enzyme tyrosinase (Riley, 1997) (Figure 1.5). Incorporation of a cysteine into 
a DOPAquinone molecule eventually leads to the production of pheomelanin rather 
than eumelanin. Additional enzymes are required for the synthesis of melanin 
including dopachrome tautomerase and dihydroxyindole-2-carboxylic acid 
(DHICA) oxidase. Control of the ratio of pheomelanin to eumelanin in a cell is 
determined by multiple factors including the cellular pH and levels of the tyrosinase 
enzyme (Ancans et al., 2001; Mitra et al., 2012). Higher levels of tyrosinase and 
neutral pH favor eumelanin production and darker pigmentation (Burchill et al., 
1986; Ancans et al., 2001). In addition, the melanocortin 1 receptor is the major 
genetic factor promoting the synthesis of eumelanin and increasing the ration of 
eumelanin:pheomelanin (further discussed below).  
 
Melanoma risk associated with skin pigmentation can be assessed via the 
Fitzpatrick skin phototype. The Fitzpatrick score determines an individual’s UV 
susceptibility based on basal pigment levels, tendency to burn, and ability to tan 
(Fitzpatrick, 1975). Individuals with a lower Fitzpatrick score have fair skin (less 
pigment), red or blonde hair, burn easily, and are unable to tan while individuals 
with a higher Fitzpatrick score have a darker complexion, do not burn, and tan  
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Figure 1.5 Eumelanin and Pheomelanin Synthesis  
Eumelanin and pheomelanin are derived from progressive cyclization 
and oxidation of the amino acid tyrosine. Tyrosinase catalyzes the 
hydroxylation of tyrosine to DOPA and then the oxidation of DOPA to 
DOPAquinone. At the level of DOPAquinone, if cAMP levels are 
elevated, DOPAquinone undergoes spontaneously cyclization to 
leuocDOPAchrome and then to DOPAchrome. DOPAchrome can be 
 16 
  leuocDOPAchrome and then to DOPAchrome. DOPAchrome can be 
spontaneously converted to either dihydroxyindole (DHI) or converted to 
dihydroxyindole-2-carboxylic acid (DHICA) via dopachrome tautomerase 
(DCT). DHICA oxidase catalyses the conversion of DHI to indole-5,6-
quinone and the conversion of DHICA to indole-5,6-hydroquinone-2-
carboxylic acid. Both indole-5,6-quinone and indole-5,6-hydroquinone-2-
carboxylic acid are then converted to eumelanin. If cAMP levels are low, 
a cysteine in incorporated with DOPAquinone to form cysteinylDOPA. 
CysteinylDOPA is oxidized and polymerized to pheomelanin.  
Abbreviations: DCT – dopachrome tautomerase; DHI – dihydroxyindole; 
DHICA – dihydroxyindole-2-carboxylic acid; DOPA – L-3,4-
dihydroxyphenylalanine; MC1R – melanocortin 1 receptor 
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easily.  The lower the Fitzpatrick score, the more susceptible an individual is to UV 
induced damage and melanoma (Gandini et al., 2005).  
 
1.4 Melanocortin 1 Receptor 
 
One of the major genetic factors associated with protection against UV induced 
damage and melanomagenesis is the melanocortin 1 receptor (MC1R). The 
human MC1R is 317 amino acids (Garcia-Borron et al., 2005) and was originally 
identified and cloned by two independent groups in 1992 (Chhajlani and Wikberg, 
1992; Mountjoy et al., 1992). MC1R is a Gs protein coupled receptor located on 
the melanocyte plasma membrane whose activation promotes multiple UV 
protective pathways including increased melanin synthesis (Suzuki et al., 1997) 
and resistance to UV injury through enhanced antioxidant defenses and 
acceleration of nucleotide excision repair (Kadekaro et al., 2012; Jarrett et al., 
2014). Following activation with agonistic ligands the Gαs protein dissociates from 
MC1R and stimulates adenylyl cyclase activity which cleaves ATP to generate 
cAMP. cAMP functions as a second messenger and activates effector proteins 
such as the cAMP-dependent protein kinase A (PKA) (Neves et al., 2002; Dorsam 
& Gutkind, 2007) which promote the UV protective pathways (Figure 1.6).  
 
1.4.1 MC1R and Pigmentation 
 
As stated above, MC1R is one of the major proteins controlling the switch between 
the production of eumelanin and pheomelanin, and is therefore a major control of 
pigment production. MC1R has low levels of constitutive ligand independent  
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Figure 1.6 MC1R is a Gs Protein Coupled Receptor 
Binding of the melanocortin 1 receptor (MC1R) by its positive agonist α 
melanocyte stimulating hormone (αMSH) activates the Gs protein bound 
to the receptor by exchanging the GDP for GTP. The Gα subunit 
dissociates from the Gβ and Gγ subunits and activates adenylyl cyclase. 
Adenylyl cyclase catalyzes the conversion of ATP to cAMP which 
functions as a second messenger and promotes the UV protective 
pathways. 
 19 
  Abbreviations: αMSH - α melanocyte stimulating hormone; MC1R – 
melanocortin 1 receptor; UV – ultraviolet  
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activity that contributes to basal pigmentation levels (Bennett & Lamoreux, 2003), 
and the ability to be activated by endogenous ligands to promote further eumelanin 
accumulation.  
 
The importance of MC1R in producing pigment is evident in murine models with 
altered MC1R signaling. Mice with the recessive yellow mutation (mutation of the 
MC1R gene extension) produce a nonfunctional MC1R and exhibit a blonde 
pheomelanotic coat color rather the darkly pigmented coat traditionally found on 
the C57/BL6 background (Searle, 1968; Robbins et al., 1993). Conversely, an 
increase in MC1R activity found in either the sombre (constitutive active receptor) 
or tobacco (hyperactive receptor) mutation is associated with an increase in 
eumelanin synthesis and a darker coat color (Robbins et al., 1993). Individuals 
with non-functional MC1R proteins also have deficient eumelanin production and 
have low levels of basal pigmentation with some variants associated with fair skin 
and reddish hair color (discussed further below) (Valverde et al., 1995). 
 
The ability of the skin to respond to UV radiation by increasing eumelanin 
production, the adaptive pigmentation pathway, is a major innate protective 
mechanism by which the skin prevents further damage from ultraviolet radiation 
and is dependent upon MC1R signaling (Figure 1.7). UV radiation causes DNA 
damage to keratinocytes in the epidermis of the skin and the subsequent increased 
expression of the POMC gene in a p53 dependent manner (Cui et al., 2007). 
Cleavage of the proopiomelanocortin (POMC) protein by proconvertase 1 and 2 
results in the generation of the MC1R positive agonist α melanocyte stimulating  
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Figure 1.7 MC1R Dependent Eumelanin Synthesis 
Binding of MC1R by its positive agonist α melanocyte stimulating 
hormone (αMSH) leads to activation of adenylyl cyclase and the 
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  generation of cAMP. cAMP activates protein kinase A (PKA) which 
phosphorylates the cAMP responsive binding element (CREB) at 
Ser133. CREB translocates to the nucleus and induces the transcription 
of micropathalmia-associated transcription factor (MITF). MITF 
subsequently functions as a transcription factor and induces the 
transcription of multiple genes involved in eumelanin synthesis including 
tyrosinase and dopachrome tautomerase.  
Abbreviations: αMSH - α melanocyte stimulating hormone; CREB – 
cAMP responsive binding element; DCT – dopachrome tautomerase; 
MC1R – melanocortin 1 receptor; MITF – micropathalmia-associated 
transcription factor; PKA – protein kinase A; POMC – 
proopiomelanocortin; TYR - tyrosinase 
 23 
hormone (αMSH) (Benjannet et al., 1991). Binding of αMSH to MC1R leads to the 
activation of adenylyl cyclase and promotes the generation of cAMP (Kadekaro et 
al., 2003; Millington, 2006). cAMP accumulation promotes the activation of PKA 
leading to the phosphorylation of the cAMP responsive binding element (CREB).  
CREB functions as a transcription factor increasing the expression of 
microphthalmia-associated transcription factor (MITF). MITF is a master 
transcription factor and leads to the increased expression of multiple enzymes 
involved in the synthesis of eumelanin including tyrosinase (Yasumoto et al., 1994; 
Bertolotto et al., 1996; Levy et al., 2006; Scherer and Kumar, 2010; Bertolotto et 
al., 2011).  
 
1.4.2 MC1R and NER 
 
Individuals with defective MC1R signaling are prone to UV induced skin cancer not 
only because they have decreased pigmentation but also because they have a 
blunted DNA repair response. We and others have reported that activation of 
MC1R and the subsequent cAMP signaling cascade are major regulators of NER 
kinetics and efficiency (Kadekaro et al., 2005; Smith et al., 2008; Jagirdar et al., 
2013; Jarrett et al., 2014). cAMP signaling directly impacts how long UV 
photodamage persists in melanocytes (Hauser et al., 2006; Abdel-Malek et al., 
2009), and repair of photodamage in the skin of mice with humanized skin due to 
expression of the K14-Scf transgene is more robust either with a functional MC1R 
protein or when pharmacologic agents that induce cAMP signaling are topically 
applied to the skin (Jarrett et al., 2014).  
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Figure 1.8 MC1R Signaling and Melanocyte Genome Integrity 
MC1R signaling promotes genomic stability through multiple 
mechanisms. MC1R activation induces translocation of nuclear receptor 
subfamily 4 group A member 2 (NR4A2) to the nucleus in a p38 and poly 
 25 
  ADP ribose polymerase (PARP) with XPC and XPE at sites of UV 
induced DNA damage. MC1R activation also leads to elevated levels of 
XPC and γH2AX promoting the formation of DNA repair complexes. 
Levels of γH2AX are regulated by Wip1 downstream of ATR and DNA-
PK mediated phosphorylation of p53 at Ser15. In addition, PKA activation 
promotes the phosphorylation of ataxia telangiectasia mutated and Rad3 
related (ATR) at Ser435. pSer435-ATR complexes with XPA in the 
nucleus. Following phosphorylation of XPA, the complex translocates to 
sites of UV induced DNA damage to accelerate and enhance nucleotide 
excision repair. 
Abbreviations: ATR – ataxia telangiectasia mutated and Rad3 related; 
DNA-PK – DNA protein kinase; MC1R – melanocortin 1 receptor; NR4A2 
– nuclear receptor subfamily 4 group A member 2; PARP – poly ADP 
ribose polymerase; PKA – protein kinase A; Wip1 – wild-type p53 
induced phosphatase 1; XP – xeroderma pigmentosum 
complementation group 
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Although it has been known for a decade that MC1R signaling accelerates NER 
kinetics (Abdel-Malek et al., 2006), the molecular mechanisms by which the 
phenomenon occurs have only recently begun to be elucidated and appear to be 
complex (Figure 1.8). Acceleration of repair of photo damage has been shown to  
be dependent upon both the nuclear receptor subfamily 4 group A member 2 
(NR4A2) and ataxia telangiectasia mutated and Rad3 related (ATR) signaling 
pathways (Smith et al., 2008; Jagirdar et al., 2013; Jarrett et al., 2014). MC1R 
signaling leads to the induction of NR4A2 which translocates to sites of 
photodamage in a p38 and poly ADP ribose polymerase (PARP) dependent 
manner. The NR4A2/PARP complex colocalizes with the DNA damage proteins 
XPC and XPE at sites of DNA damage. Data suggests that NR4A2 may play a role 
in promoting chromatin relaxation to promote DNA repair (Smith et al., 2008; 
Jagirdar et al., 2013).  
 
Recently, we reported that enhancement of NER by cAMP is dependent upon a 
post-translational modification of ATR. Stimulation of MC1R by melanocortins or 
pharmacologic cAMP induction causes PKA to phosphorylate ATR at Ser435. 
Phosphorylated ATR forms a complex with XPA and recruits XPA to sites of 
photodamage enhancing repair and preventing mutagenesis (Jarrett et al., 2014). 
 
Activation of MC1R has also been shown to facilitate repair via an increase in DNA 
damage response proteins. Treatment with αMSH leads to an increase in XPC and 
γH2AX levels promoting formation of DNA repair complexes in primary human 
melanocytes (Swope et al., 2014).  There is also a concomitant increase in DNA 
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repair gene expression dependent upon MC1R signaling (Kadekaro et al., 2010; 
Strub et al., 2011). In addition, MC1R also promotes the return to homeostasis via 
p53 signaling. MC1R activation promotes the phosphorylation of p53 at Ser15 in 
an ATR and DNA-PK dependent fashion leading to activation of wild-type p53 
induced phosphatase 1 (Wip1) and degradation of γH2AX (Kadekaro et al., 2012; 
Swope et al., 2014). 
 
1.4.3 Hormonal Regulation of MC1R  
 
MC1R signaling is complex and dynamic and is heavily influenced by receptor 
interactions with its ligands: the positive agonist melanocortins, the negative 
agonist agouti signaling protein (ASIP), or the neutral antagonist β-defensin 3 
(βD3) (Figure 1.9).  All three ligands function as competitive inhibitors of each other 
as binding of any one ligand to MC1R is mutually exclusive (Ollmann et al., 1998; 
Swope et al., 2012; Nix et al., 2013).  
 
There are four endogenous melanocortins: αMSH, βMSH, γMSH, and 
adrenocorticotropic hormone (ACTH) which are derived as cleavage products from 
the proopiomelanocortin (POMC) protein (Wintzen & Gilchrest, 1996) (Figure 
1.10). A byproduct of POMC cleavage is the generation of β-endorphin which is 
active at opiate receptors in the skin (Wintzen & Gilchrest, 1996). The UV-
dependent β-endorphin production and the resultant opiate “high” is believed to 
contribute to UV-seeking behavior (Fell et al., 2014). The two major melanocortins 
in the skin are αMSH and ACTH (Abdel-Malek et al., 2000). Binding of αMSH or 
ACTH to MC1R results in an increase in cAMP levels and the promotion of the   
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AC
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MC1R
cAMP Cutaneous 
UV Protection
ASIP βD3 αMSH
Figure 1.9 MC1R Ligands 
 Three of the main ligands for MC1R are α melanocyte stimulating 
hormone (αMSH), β-defensin 3 (βD3), and agouti signaling protein 
(ASIP). The melanocortin αMSH functions as a positive agonist, and 
binding of αMSH to MC1R results in activation of adenylyl cyclase (AC) 
and an increase in cAMP signaling. ASIP functions as an inverse agonist, 
and binding of ASIP to MC1R decreases adenylyl cyclase activity. βD3 
is a neutral antagonist, and binding of βD3 to MC1R does not affect 
adenylyl cyclase activity or cAMP levels.  All three ligands function as 
competitive inhibitors, and binding of one ligand precludes binding of the 
others. 
Abbreviations: AC – adenylyl cyclase; MC1R – melanocortin 1 receptor 
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Figure 1.10 Melanocortin Synthesis via Proopiomelanocortin (POMC) 
Processing 
Melanocortins are derived from the proopiomelanocortin (POMC) 
precursor peptide. It is cleaved into functional protein fragments via a pair 
of serine proteases proprotein convertase (PC) 1 and 2. PC1 cleaves 
POMC into four subunits including an N-terminal region, a junctional 
protein (JP), adrenocorticotropic hormone (ACTH), and β lipotropin 
(βLPH). The N-terminal is cleaved by PC2 to produce γ melanocyte 
stimulating hormone (MSH). ACTH is cleaved by PC2 to generate αMSH 
and the corticotropin like intermediate peptide (CLIP). βLPH is cleaved 
by PC2 generate γLPH and β endorphin. γLPH is subsequently cleaved 
by PC2 to generate βMSH. 
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  Abbreviations: ACTH – adrenocorticotropic hormone; CLIP – 
corticotropin like intermediate peptide; JP – junctional protein; βLPH - β 
lipotropin; MSH – melanocyte stimulating hormone; PC – proconvertase  
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MC1R dependent UV protective pathways: accumulation of eumelanin and 
acceleration of NER. ASIP functions to decrease MC1R signaling via two 
mechanisms. First, it acts as a competitive MC1R inhibitor preventing αMSH from 
binding to MC1R inhibiting melanocortin induced MC1R activation (Blanchard et 
al., 1995). In addition, ASIP also functions as an inverse agonist and reduces basal 
MC1R signaling (Lu et al., 1994; Wilson et al., 1995). Binding of ASIP to MC1R 
prevents αMSH induced tyrosinase, tyrosine related proteins 1 and 2, and MITF 
expression suppressing melanogenesis (Aberdam et al., 1998), and in addition, 
decreases basal tyrosinase activity and tyrosinase and tyrosinase related protein 
1, 2, and 3 levels (Sakai et al., 1997; Abdel-Malek et al., 2001). ASIP signaling 
also affects NER, and treatment with ASIP decreases both basal NER kinetics in 
a dose dependent manner (Jarrett et al., 2015) and prevents the acceleration of 
NER downstream of αMSH  (Jarrett et al., 2014; Jarrett et al., 2015). 
 
βD3 belongs to a group of antimicrobial peptides that link the innate and adaptive 
immune responses and was only shown to interact with MC1R within the last 
decade (Candille et al. 2007). Although binding of βD3 to MC1R does not affect 
basal cAMP levels (Swope et al., 2012; Nix et al., 2013), it competes with both 
ASIP and αMSH preventing them from binding and altering MC1R signaling. βD3 
prevents αMSH induction of the pigment pathway (Swope et al., 2012) and inhibits 
the phosphorylation of ATR by PKA at Ser435 and the subsequent enhancement 
of DNA repair downstream of αMSH (Jarrett et al., 2015).  
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1.5. Targeting the Melanocortin-MC1R Signaling Axis 
 
MC1R is a highly polymorphic protein with over 100 variants reported in the human 
population (Seabrook et al., 2005; Gerstenblith et al., 2007; Perez Oliva et al., 
2009) . Five specific variants, D84E, R142H, R151C, R160W, and D294H, result 
in MC1R loss-of-function and are associated with a decrease in pigment 
production and the “red hair color” (RHC) phenotype (Valverde et al., 1995; Box et 
al., 1997; Flanagan et al., 2001). Individuals with RHC variant mutations have an 
increased sensitivity to UV exposure and elevated melanoma risk because they 
are unable to prevent and repair UV damage. They have decreased eumelanin 
synthesis and therefore have low basal pigmentation and an inability to tan. These 
individuals burn easily and accumulate a greater degree of UV induced damage. 
They also cannot accelerate their DNA repair, therefore, the damage they sustain 
is not repaired as quickly and is more likely to result in mutation (Bohm et al., 2005; 
Hauser et al., 2006).  
 
Pharmacologic enhancement of the MC1R pathway represents a major 
opportunity to augment the innate UV protective pathways to prevent development 
of skin cancer. MC1R signaling can be manipulated either via melanocortin 
analogs (Abdel-Malek et al., 2006) to directly stimulate MC1R or by bypassing the 
receptor and increasing cAMP levels by activating adenylyl cyclase (i.e. forskolin) 
(D’Orazio et al., 2006) or inhibiting cAMP degradation via a phosphodiesterase 
inhibitor (i.e. rolipram) (Khaled et al., 2010). Although melanocortin analogs do 
require a functional MC1R, and therefore, could not be utilized in the RHC 
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population, they offer a melanocyte specific targeted approach. Topical application 
of forskolin or rolipram, however, would result in an increase in cAMP signaling 
throughout the skin as both forskolin and rolipram bypasses MC1R and directly 
increase cAMP levels.  
 
Although the activation of the UV protective pathways downstream of MC1R is 
beneficial, unregulated enhancement of MC1R signaling has the potential for 
dangerous consequences. MC1R activation, in addition to promoting the UV 
protective signaling pathways, also promotes melanocyte proliferation (Suzuki et 
al., 1996; Kadekaro et al., 2003) (Figure 1.11). Physiologically, the interaction of 
the positive and inhibitory ligands prevents the receptor from constant activation. 
Pharmacologic enhancement of MC1R signaling that bypasses the receptor, 
however, cannot be innately regulated. Consequently, augmentation of the MC1R 
signaling axis has the risk for uncontrolled melanocyte proliferation and 
melanomagenesis. In theory, in order for this approach to be safe in humans, the 
risk for melanocyte proliferation must be negligible, therefore, it is important to 
better understand the signaling mechanism by which MC1R promotes melanocyte 
proliferation. 
 
1.6 Overall Scope of This Dissertation 
 
The overall goal of this dissertation is to further elucidate the complexities of MC1R 
signaling, and specifically to assess the interdependence of the pigmentation, 
NER, and proliferation pathways to determine whether any one pathway could be 
selectively augmented or inhibited in a translationally relevant manner. Both the  
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Figure 1.11 Pharmacologic Manipulation of MC1R 
 MC1R signaling can be pharmacologically manipulated either directly 
via α melanocyte stimulating hormone (αMSH) analogs or via forskolin 
which bypasses the receptor and directly activates adenylyl cyclase. 
αMSH analogs can only be used for individuals with a functional MC1R 
protein while activation of adenylyl cyclase can be used for individuals 
with a loss-of-function MC1R protein. cAMP stimulus results in activation 
of three pathways: 1) induction of eumelanin synthesis, 2) acceleration 
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  of NER, and 3) induction of melanocyte proliferation 
Abbreviations: αMSH - α melanocyte stimulating hormone; AC – adenylyl 
cyclase; MC1R – melanocortin 1 receptor 
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induction of eumelanin synthesis and the acceleration of NER are well 
characterized and dependent upon PKA signaling downstream of MC1R and 
cAMP. MC1R induced melanocyte proliferation is less well understood. In order to 
determine whether the three pathways can be independently manipulated 
pathways, the interdependence between the pathways must first be determined. 
The specific aims of this dissertation were: 1) to determine the role of UV in the 
regulation of the expression of the MC1R neutral antagonist βD3, 2) to directly test 
the interdependence and cross talk between the two UV protective pathways, and 
3) to determine the mechanism by which MC1R promotes melanocyte proliferation 
and to determine whether MC1R proliferation can be selectively inhibited while 
maintaining eumelanin synthesis and the acceleration of NER downstream of 
MC1R. The overall hypothesis of this dissertation is that the three pathways 
downstream of MC1R can be independently manipulated to protect against UV 
induced damage. 
 
Chapter 2 investigates the regulation of the MC1R neutral antagonist βD3 gene. 
UV naïve human neonatal foreskins were utilized to assess the role of 
inflammation and UVB induced DNA damage on the induction of βD3 mRNA 
expression.  
 
Chapter 3 investigates the interaction and cross talk between the two UV protective 
pathways downstream of MC1R: the induction of eumelanin synthesis and the 
acceleration of NER. Primary human melanocytes and transformed human 
melanoma cell lines were utilized to assess the role of the MITF transcription factor 
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in the acceleration of DNA repair and the role of ATR in the activation of the 
adaptive pigmentation pathway. 
 
Chapter 4 investigates the role of mTOR on MC1R induced melanocyte 
proliferation and the interaction between the proliferation pathway and the UV 
protective pathways downstream of MC1R (the induction of eumelanin synthesis 
and acceleration of NER). A transformed melanoma cell line was utilized to 
determine the signaling pathway responsible for MC1R induced proliferation. In 
addition, a transformed melanoma cell line and an MC1R-null murine mouse model 
were used to assess the potential to selectively manipulate and inhibit MC1R 
induced proliferation while maintaining the UV protective pathways in vitro and in 
vivo. 
 
In summary, primary human melanocyte and transformed human melanoma cell 
lines in addition to an MC1R null-murine mouse model and human neonatal 
foreskin explants were utilized to further elucidate the regulation of MC1R ligands 
and signaling pathways. 
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Chapter 2: UV-Independent Induction of Beta Defensing 3 in Neonatal 
Human Skin Explants 
 
________________________________________________________________ 
 
Adapted from Wolf Horrell E. and D’Orazio J. (2015). UV-Independent 
Induction of Beta Defensing 3 in Neonatal Human Skin Explants. 
F1000Research 3, 288.  
 
2.1 Introduction 
 
The melanocortin 1 receptor (MC1R) is a Gs protein coupled receptor expressed 
on melanocytes that regulates several key aspects of cutaneous UV responses. 
When bound by agonistic ligands, most notably α melanocyte stimulating hormone 
(αMSH) (Suzuki et al., 1996), MC1R initiates a cascade of UV-protective events 
mediated by activation of adenylyl cyclase and generation of cAMP that result in 
melanin production and enhanced genome stability via enhancement of DNA 
repair (Kadekaro et al., 2005). In addition to αMSH, MC1R signaling is regulated 
by other soluble ligands, most notably agouti signaling protein (ASIP) which 
antagonizes MC1R signaling, decreases cAMP levels, and diminishes 
downstream melanocyte responses such as pigment induction (Millar et al., 1995; 
Suzuki et al., 1997). Recently, it has become clear that β-defensin 3 (βD3), known 
for its role in innate antimicrobial immunity, binds and influences MC1R signaling 
as a neutral MC1R agonist that blunts αMSH-mediated MC1R activation as well 
as ASIP-mediated MC1R antagonism (Candille et al., 2007; Kaelin et al., 2008; 
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Beaumont et al., 2012; Swope et al., 2012). Thus, βD3 may be an important 
regulator of MC1R-dependent melanocyte responses in the skin. 
 
Because UV radiation is a major causative agent for melanoma and other skin 
cancers and because MC1R signaling mediates critical UV-protective responses 
such as melanization of the skin and melanocytic resistance to UV mutagenesis, 
it is important to understand how UV affects expression of MC1R ligands in the 
skin. αMSH levels increase in response to UV exposure of the skin. Cui and 
coworkers reported that UV promoted transcriptional increases in 
proopiomelanocortin (POMC), the protein precursor for αMSH, in a cell damage 
and p53-dependent manner in epidermal keratinocytes (Cui et al., 2007), 
supporting the hypothesis that melanocytic MC1R responses are modified by 
intracutaneous UV-regulated mechanisms. Similarly, recent studies reported that 
UVB radiation caused an increase βD3 mRNA and protein levels both in vivo and 
in vitro (Glaser et al., 2009), either in a cell-autonomous, damage-dependent 
manner or in response to inflammatory mediators such as interleukin-1 (IL-1β) and 
tumor necrosis factor-α (TNFα) known to promote its induction (Jia et al., 2001; 
Harder et al., 2001). In an effort to understand the mechanisms of how βD3 
production may be influenced by UV radiation, we determined its expression in 
freshly isolated human skin explants. Here we report that βD3 expression 
increases in a UV-independent manner in neonatal human skin explants in 
response to processing and culturing of tissues ex vivo. 
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2.2 Methods 
 
2.2.1 Neonatal Foreskin Explants  
 
Freshly-isolated, de-identified neonatal foreskins were collected from normal 
newborn infants undergoing planned circumcision from the University of Kentucky 
Birthing Center under an IRB-exempted protocol. Foreskins were collected only 
from patients who were consented prior to delivery. Samples were placed into 30 
mL of Roswell Park Memorial Institute (RPMI) media (Life Technologies) and 
stored at room temperature for a maximum of four hours before processing. 
Samples were rinsed in phosphate buffered saline (PBS) + 1% penicillin 
streptomycin (Life Technologies), and dermal fat was manually removed by 
forceps to the point that explants would lie completely flat. Explants were placed 
in 3 cm cell culture dishes and floated dermal side down on 3 mL of RPMI media 
with 10% fetal bovine serum for 16–18 hours at 4°C until use. Prior to UV 
treatment, explants were divided into roughly equal-sized pieces. Following UV 
treatment, explants were maintained in 3 mL of RPMI + 10% fetal bovine serum + 
1% penicillin streptomycin in a humidified incubator at 37°C with 5% CO2. The 
media was changed every 48 hours. 
 
2.2.2 Skin Color Measurement 
 
Skin reflective colorimetry was assessed with a CR-400 Colorimeter (Minolta 
Corporation) calibrated against a white background. Degree of melanization 
(darkness) was quantified as the colorimetric measurement on the *L axis (white-
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black axis) of the CIE standard color axis (Wagner et al., 2002). The degree of 
pigmentation was determined by three independent measurements for each 
sample. 
 
2.2.3 Ex Vivo UV Exposure  
 
Skin explants were exposed (epidermal side up) to an overhead double bank of 
UVB lamps (UV Products) to receive 0.5 kJ/m2 UVB, a dose similar to that reported 
previously with respect to cutaneous βD3 induction in vivo (Glaser et al., 2009; 
Hong et al., 2008). UV emittance was measured with a Model IL1400A handheld 
flash measurement photometer (International Light) equipped with separate UVB 
(measuring wavelengths from 265–332 nm; peak response at 290 nm) and UVA 
(measuring wavelengths from 315–390 nm; peak response at 355 nm) filters 
corresponding to International Light product numbers TD# 26532 and TD# 27108 
respectively. Spectral output of the lamps was determined to be roughly 75% UVB 
and 25% UVA. Following exposure to UV radiation, samples were flash frozen at 
the indicated times for further processing. 
 
2.2.4 Hematoxylin and Eosin Tissue Staining  
 
Four neonatal skin explants were divided into two biopsies. One biopsy was 
untreated and harvested at time 0. The other was exposed to 0.5 kJ/m2 UVB 
radiation and harvested at 24 hours. The biopsies were placed in 4% 
paraformaldehyde for 48 hours to fix the sample and subsequently placed in 70% 
ethanol. Samples were embedded in paraffin. Samples were processed, sectioned 
 42 
at a thickness of 4 µm and stained for hematoxylin and eosin (Dako) by the 
University of Kentucky Markey Cancer Center Biospecimen and Tissue 
Procurement Shared Resource Facility. 
 
2.2.5 mRNA Isolation  
 
Total RNA was harvested from skin using TRIzol (Life Technologies). 25 mg of 
sample were placed in 500 µL of TRIzol and ground to a fine consistency using a 
dounce homogenizer. Homogenized sample was incubated for 5 minutes at room 
temperature. 100 µL of chloroform were added to each sample, and each sample 
was shaken vigorously for 15 seconds. Sample was incubated for 2–3 minutes at 
room temperature. Sample was centrifuged at 12,000 × g for 15 minutes at 4°C. 
RNA was isolated in the aqueous phase. RNA was precipitated with 250 µL of 
isopropanol. Sample was incubated at room temperature for 10 minutes and then 
centrifuged at 12,000 × g for 10 minutes at 4°C. Supernatant was removed. The 
RNA pellet was washed with 500 µL of ethanol and centrifuged at 7,500 × g for 5 
minutes at 4°C. Supernatant was removed and the RNA pellet was dissolved in 50 
µL RNase DNase free distilled water. RNA concentration was determined utilizing 
a Nanovue nanodrop (GE Healthcare). 
 
2.2.6 Reverse Transcriptase Polymerase Chain Reaction (RTPCR) 
 
1 µg of RNA was reverse transcribed to cDNA utilizing random hexamers and M-
MLV reverse transcriptase (Promega) in a Mastercycler epgradient thermocycler 
(Eppendorf International). cDNA was diluted 1:10 in RNase DNase free distilled 
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water for use in quantitative real time polymerase chain reaction. 
 
2.2.7 Quantitative Real Time Polymerase Chain Reaction (qRTPCR) 
 
Quantitative real time polymerase chain reaction (qRTPCR) analysis was 
performed using an Applied Biosystems 7500 Real Time PCR System (Life 
Technologies) (10 ng cDNA/reaction) utilizing TATA-binding protein (TBP) as a 
reference gene. Primer sets for TBP were 5´-CAGCGTGACTGTGAGTTGCT-3’ 
(left) and 5´-TGGTTCATGGGGAAAAACAT-3’ (right), for βD3 were 5´-
TAGGGAGCTCTGCCTTACCA-3’ (left) and 5´-CACGCTGAGACTGGATGAAA-3’ 
(right), for TNFα were 5´-TCCTTCAGACACCCTCAACC-3’ (left) and 5´-
AGGCCCCAGTTTGAATTCTT-3’ (right), and for tyrosinase were 5´-
TACGGCGTAATCCTGGAAAC-3’ (left) and 5´-ATTGTGCATGCTGCTTTGAG-3’ 
(right) (Integrated DNA Technologies). 
 
2.2.8 Statistics and Data Analysis 
 
Correlation and linear regression analysis were performed using GraphPad Prism 
5.0 (GraphPad Software). Data were considered statistically significant if p values 
were less than 0.05 from multiple independent experiments. 
 
2.3 Results 
 
2.3.1 βD3 Induction is Independent of Skin Pigmentation 
 
To understand the effects of UV radiation on βD3 expression in human skin, 
freshly-isolated foreskins were exposed to 0.5 kJ/m2 UVB. Fourteen de-identified 
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samples were obtained from normal healthy male infants undergoing elective 
circumcision before discharge from the neonatal nursery. Skin pigmentation was 
measured for each sample three independent times by reflective colorimetry in 
order to estimate melanin content of the epidermis. The skin samples exhibited a 
range of melanization as determined by the *L score which quantifies color on a 
black-white color axis (a lower *L score is indicative of a blacker/darker color and 
correlates with epidermal eumelanin content (D’Orazio et al., 2006)). The majority 
of the samples were derived from light-skinned infants, however at least 3 samples 
were darker in color (Figure 2.1).  
 
Skin explants were exposed to 0.5 kJ/m2 UVB, and biopsies were taken from the 
explants at 6, 12, 24, 48, and 72 hours following UV exposure. βD3 mRNA 
expression was measured by qRTPCR at 6, 12, 24, 48 and 72 hours after radiation, 
normalized to TBP, and compared to an unirradiated control taken at time 0. Due 
to the small size of the skin explants (roughly 1 cm2), it was not possible to have a 
time-matched mock-irradiated control at each time point, therefore values were 
normalized to unirradiated controls from each skin sample. We noted extensive 
variability in both the timing and magnitude of βD3 induction across individuals 
(Figure 2.2 A). Normalized βD3 fold induction ranged from 1.3-fold to 44.8-fold, 
and peak induction ranged from 6–72 hours depending on the sample (Figure 2.2 
B). We tested whether the amount of βD3 expression correlated with skin 
pigmentation, hypothesizing that more melanin in the skin might inhibit UV 
penetration into the skin and therefore blunt UV effects on βD3 expression. In fact, 
βD3 expression did not appear to be influenced by pigment phenotype, as 
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Figure 2.1 Degree of Skin Pigmentation from Each Donor 
Skin color determination is shown for each sample. *L Score is measured 
by reflective colorimetry and represents color of the skin on a black-white 
axis. Lower *L score is indicative of a more darkly pigmented phenotype. 
Data represent the average *L score ± SEM for three measurements per 
skin sample.   
(Adapted from Wolf Horrell and D’Orazio, 2015) 
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Figure 2.2 βD3 mRNA Induction Varies Between Individuals 
A) Fourteen independent human skin explants (Samples A–N) were 
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  treated ex vivo with 0.5 kJ/m2 UVB radiation. βD3 mRNA expression was 
determined at 6, 12, 24, 48, and 72 hours following UV treatment and 
compared to untreated matched controls.  
B) Time of maximal βD3 expression after UV radiation across samples. 
Peak βD3 mRNA expression for human skin explants (n=14) is arranged 
by time of maximal induction for each individual donor. qRTPCR was 
performed in duplicate for each sample, and results are expressed as 
mean fold change over control ± SEM. 
(Adapted from Wolf Horrell and D’Orazio, 2015) 
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manifested by a positive trend between higher βD3 expression and darker skin 
samples (Figure 2.3 A; r2 = 0.057, p = 0.41). Similarly, a negative trend between 
skin color and time of peak βD3 expression was observed, although this too did 
not reach statistical significance (Figure 2.3 B; r2 = 0.234, p = 0.08). 
 
2.3.2 βD3 Induction in Skin Explants is Independent of UV Exposure 
 
We then considered the possibility that βD3 expression might be affected simply 
by time in culture and measured βD3 expression over time in samples exposed to 
0 or 0.5 kJ/m2 UVB exposure. Each of five explants were divided into three sections 
and sampled either at time 0 (no UV) or at 24 hours following exposure to either 0 
or 0.5 kJ/m2 UVB. Similar to prior experiments, βD3 expression was measured by 
qRTPCR and normalized to TBP, however values could also be compared with 
mock-irradiated, time-matched conditions. We observed clear induction of βD3 
expression in each of the mock-irradiated samples over time (Figure 2.4 A), and 
exposure to 0.5 kJ/m2 UVB did not substantially alter βD3 mRNA expression when 
compared to individual mock-irradiated time-matched controls. We assessed 
whether the processing of the samples led to sample degradation via 
immunohistochemistry. Staining revealed that after 24 hours of ex vivo treatment, 
the samples appeared similar to those at time 0 and suggested their viability 
(Figure 2.4 B). These data suggest that either tissue removal or the process of 
culturing skin explants ex vivo in our culture conditions is sufficient to enhance βD3 
expression in whole human neonatal skin and that the addition of 0.5 kJ/m2 UVB 
does not impact βD3 expression in this setting. 
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Figure 2.3 Relationship Between Donor Skin Color and βD3 Expression 
A) *L score versus peak βD3 mRNA induction. qRTPCR was performed 
in duplicate for each sample, and data represent mean βD3 induction for 
14 human skin explants. There was no correlation between donor *L 
score and amplitude of βD3 induction (r2 = 0.057, p = 0.41).  
B) *L score versus time of peak βD3 mRNA induction. qRTPCR was 
performed in duplicate for each sample, and data represent mean βD3 
induction for 14 human skin explants. Although a weak negative trend 
existed between donor *L score and time of βD3 induction, the correlation 
was not statistically significant (r2 = 0.234, p = 0.08). 
(Adapted from Wolf Horrell and D’Orazio, 2015). 
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Figure 2.4 UV-independent βD3 Expression in Human Skin Explants 
Cultured Ex Vivo 
A) UVB independent induction of βD3. Five human neonatal skin 
explants (Samples O–S) were treated ex vivo with 0.5 kJ/m2 UVB 
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  radiation. βD3 mRNA expression of UV-treated samples and unirradiated 
time-matched controls were compared to unirradiated time-matched 
controls taken at time 0. qRTPCR was performed in duplicate for each 
sample, and data represent the mean fold change over the untreated 
control taken at the time of UV treatment ± SEM.  
B) Histological analysis of neonatal skin samples at time 0 or 24 hours 
after UVB irradiation (0.5 kJ/m2; Samples T–W). Tissues were stained 
with hematoxylin and eosin to assess tissue degradation. 
(Adapted from Wolf Horrell and D’Orazio, 2015) 
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2.3.3 βD3 Induction In Skin Explants Correlated with TNFα Levels 
 
Because cytokines, particularly TNFα are known to regulate βD3 expression, we 
tested whether TNFα gene expression was induced in the human neonatal skin 
samples following UV radiation. TNFα mRNA levels were assessed via qRTPCR 
at 6, 12, 24, 48, and 72 hours following UVB radiation, normalized to TBP, and 
compared to unirradiated controls. TNFα mRNA levels increased with time after 
UV in the majority of samples tested (Figure 2.5 A). Normalized TNFα mRNA 
induction ranged from 0–14.3 fold across samples. TNFα and βD3 induction 
weakly correlated over time (Figure 2.5 B, r2 = 0.335, p<0.0001) suggesting a 
relationship between the two genes. UV-independent TNFα induction was then 
assessed in four additional samples. We observed that in three of four samples, 
TNFα expression increased in culture without UV (Figure 2.6), suggesting that 
tissue processing may increase TNFα levels independently from UV. 
 
We then assessed whether ex vivo culture conditions used in these experiments 
affected other genes known to be regulated following UV radiation. Tyrosinase 
gene expression was measured in four human neonatal skin samples 24 hours 
after mock- or UV-irradiation. UV increased levels of tyrosinase gene expression 
in two of the four samples (Figure 2.7), suggesting that these culture conditions 
may be appropriate for other genes if properly controlled. 
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Figure 2.5 TNFα mRNA Induction in Human Skin Explants Cultured Ex 
Vivo 
A) TNFα expression over time among 14 distinct donors after UV 
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  radiation. Fourteen independent neonatal human skin explants (Samples 
A–N) were treated ex vivo with 0.5 kJ/m2 UVB radiation. TNFα mRNA 
expression was determined at 6, 12, 24, 48, and 72 hours following UV 
treatment and compared to matched untreated controls.  
B) Correlation of βD3 and TNFα mRNA expression over time. βD3 and 
TNFα mRNA expression were compared among fourteen human skin 
explants (Samples A–N) at 0, 6, 12, 24, 48, and 72 hours. βD3 and TNFα 
mRNA expression correlated over time (r2 = 0.335, p<0.0001). qRTPCR 
was performed in duplicate for each sample, and results are expressed 
as mean fold change over control ± SEM. 
(Adapted from Wolf Horrell and D’Orazio 2015) 
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Figure 2.6 UV-independent TNFα Expression in Human Skin Explants 
Cultured Ex Vivo 
UVB independent induction of TNFα. Four neonatal human skin explants 
(Samples O–R) were treated ex vivo with 0.5 kJ/m2 UVB radiation. TNFα 
mRNA expression for UV-treated biopsies and unirradiated time-
matched controls were compared to unirradiated tissue-matched 
controls taken at time 0. qRTPCR was performed in duplicate for each 
sample, and data represent the mean fold change over the untreated 
control taken at the time of UV treatment ± SEM. 
(Adapted from Wolf Horrell and D’Orazio, 2015) 
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Figure 2.7 Tyrosinase mRNA Expression in Human Skin Explants Cultured  
Ex Vivo 
Four neonatal human skin explants (Samples O–R) were treated ex vivo 
with 0.5 kJ/m2 UVB radiation. Tyrosinase mRNA expression was 
determined for UV treated biopsies and unirradiated time-matched 
controls and compared to tissue-matched unirradiated controls taken at 
time 0. qRTPCR was performed in duplicate for each sample, and data 
represent the mean fold change over the untreated control taken at the 
time of UV treatment ± SEM. 
(Adapted from Wolf Horrell and D’Orazio, 2015). 
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2.4 Conclusions/Discussion 
 
In an effort to develop a model in which to study UV induction of cutaneous βD3, 
we measured its expression over time in UV-naïve human skin explants. Although 
there was a high degree of variability in the magnitude and kinetics of βD3 
induction between samples harvested from different donors, we observed βD3 up-
regulation in each case. To control for the possibility that tissue processing and/or 
ex vivo culture conditions might impact βD3 expression in the explants, we 
compared βD3 mRNA levels between mock-irradiated versus UV-treated sections 
of skin samples harvested from the same donor. This experiment, which included 
samples from five donors, indicated that βD3 expression increased over time 
irrespective of UV exposure (at 0.5 kJ/m2), suggesting that βD3 expression is 
induced in human skin explants in a UV-independent manner. 
 
βD3 expression has been reported to be up-regulated in wound healing processes 
(Kesting et al., 2010), therefore it might be plausible that its increase over time in 
skin explants may be related to normal wound physiologic processes activated by 
surgical excision of the skin and/or its processing after harvest. The small size of 
the skin samples isolated from neonatal circumcision (on average 1–1.5 cm2) 
implies that the majority of the tissue in the explant will be in close proximity to at 
least one cut surface, raising the possibility of local trauma-induced factors 
contributing to βD3 expression in the samples. TNFα is an inflammatory cytokine 
known to be upregulated in the wound healing process, and TNFα mRNA was also 
induced in the skin samples independently from UV radiation. TNFα induction over 
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time correlated with βD3 mRNA induction providing further support that βD3 
induction in the skin explants may be related to normal wound healing processes. 
 
Our data do not rule out the possibility that the wounding response following 
surgical excision and processing may be sufficiently robust as to prevent further 
induction by UV. Tyrosinase mRNA levels, however, were induced following UV 
radiation in 50% of the samples suggesting some genes regulated by UV can be 
induced in our ex vivo model. Alternatively, it is possible that one or more factors 
involved in sustaining the skins in culture (media, temperature, oxygen tension, 
pH, etc.) may have promoted βD3 expression in the explants. We do not as yet 
understand the mechanism(s) underlying variability of βD3 induction amplitude or 
kinetics observed between samples, however it is possible that wounding or 
inflammatory responses induced by tissue removal may vary between normal 
individuals. 
 
Previous studies have utilized adult human skin explants and reported an induction 
of βD3 mRNA following UV radiation in ex vivo culture conditions (Glaser et al., 
2009). It is possible that neonatal skin explants behave differently than adult skin 
explants, accounting for the inconsistent results between the two studies. In 
general, neonatal immune responses are less mature than those of adults, 
perhaps contributing to these observations. In addition, prior UV exposures of 
adult-derived skin tissues may not be controlled as are skin explants from UV-
naïve neonatal foreskins which may also impact results. We conclude that because 
of confounding variables involved in their generation and maintenance, neonatal 
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foreskin explants processed via the conditions outlined above may not be an 
appropriate model to isolate the effects of UV on βD3 expression in the skin, 
however other models may still be appropriate. 
 
2.5 Consent 
 
De-identified neonatal foreskin samples were obtained from the University of 
Kentucky’s Chandler Medical Center Newborn Nursery without accompanying 
clinical information under an institutionally-reviewed IRB-exempted status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Erin Marissa Wolf Horrell 2016 
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________________________________________________________________ 
Chapter 3: MC1R Enhanced DNA Repair is Independent of MITF but 
Pigment Induction Depends on ATR 
________________________________________________________________ 
3.1 Introduction 
Loss-of-function polymorphisms in the melanocortin 1 receptor (MC1R) signaling 
axis represent a major inherited risk factor for melanoma (Valverde et al., 1995; 
Kennedy et al., 2001), which currently affects nearly 1 in 50 people in the United 
States and accounts for more than 80% of skin cancer deaths (Surveillance, 
Epidemiology, and End Results, February 2016). Ultraviolet (UV) radiation is a 
major environmental driver of melanoma, as evidenced by the abundance of UV-
signature pyrimidine transitional mutations in many melanomas (Brash et al. 1991; 
Hodis et al., 2012; Shain et al., 2015). UV signature mutations result from the 
formation of UV photoproducts including pyrimidine 6,4 pyrimidone photoproducts 
(6,4 PPs) and cyclobutadipyrimidine dimers (CPDs), which if not repaired in a 
timely manner, can result in mutations and promote carcinogenesis (Brash and 
Haseltine, 1982).  
MC1R is a Gs protein coupled receptor located on the melanocyte cell membrane 
that is integral to melanocytic UV responses. Activation of the receptor following 
exposure to UV results in the induction of two major protective pathways to blunt 
and repair UV damage in melanocytes: 1) increase in eumelanin synthesis 
(adaptive pigmentation) (D'Orazio et al., 2006; Cui et al., 2007) and 2) acceleration 
 61 
of nucleotide excision repair (NER), the genome maintenance pathway chiefly 
responsible for the removal of UV photoproducts from nuclear DNA (Bohm et al., 
2005; Hauser et al., 2006; Jagirdar et al., 2013; Jarrett et al., 2014; Smith et al., 
2008).  
MC1R signaling results in the accumulation of cAMP and activation of protein 
kinase A (PKA) (Kadekero et al., 2003; Millington et al., 2006), however how the 
downstream responses are regulated is incompletely understood. Induction of 
eumelanin synthesis is largely dependent upon PKA mediated phosphorylation of 
the cAMP responsive binding element (CREB) transcription factor at Ser133 and 
subsequent induction of the microphthalmia-associated transcription factor (Mitf) 
gene (Bertolotto et al., 1998; Price et al., 1998). In turn, MITF promotes the 
transcription of enzymes responsible for the synthesis of eumelanin including 
tyrosinase and dopachrome tautomerase (Levy et al., 2006). Recently, we 
reported that MC1R signaling accelerates NER through PKA’s phosphorylation of 
the ataxia telangiectasia mutated and Rad3 related (ATR) protein at Ser435. 
pSer435-ATR complexes with xeroderma pigmentosum complementation group A 
(XPA) thereby recruiting XPA to sites of photodamage enhancing repair and 
preventing mutagenesis (Jarrett et al., 2014).  
Studies have begun to address the interaction between the two pathways. 
Activation of the pigment pathway and the accumulation of eumelanin have been 
shown to limit the extent of UV induced DNA damage, however, only MC1R 
function and not the presence of pigment affected the kinetics of DNA repair 
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(Hauser et al., 2006). MITF is a basic helix-loop-helix protein that functions as a 
global transcription factor and has been shown to induce genes associated with 
NER including RPA2 and POLE2 among others (Strub et al., 2011). This paper 
intends to further assess the cross talk between the pigmentation and repair 
pathways and directly test the role of MITF on NER and ATR on pigmentation. 
3.2 Methods  
3.2.1 Cell Lines and Pharmacologic Treatments  
Transformed melanoma SK-MEL-2 (ATCC) cells and primary human melanocytes 
(Coriell Institute for Medical Research) were cultured in Roswell Park Memorial 
Institute (RMPI) media (Life Technologies) with 10% fetal bovine serum and 
Cascade Biologics Medium 254 (Life Technologies) respectively. Forskolin (LC 
Laboratories) and VE-821 (Selleckchem) were utilized as indicated. siRNA 
targeted to ATR (Dharmacon) and MITF (Dharmacon) were performed according 
to the manufacturer’s instructions.  
3.2.2 UV Exposure In VItro 
Cells were treated with 0.1% ethanol vehicle, 10 µM forskolin, 10 µM VE-821, or a 
combination of 10 µM forskolin and 10 µM VE-821 as indicated for 1 hour prior to 
UV exposure. UV radiation was measured via a Model IL1400A handheld flash 
measurement photometer (International Light) with a UVB filter (assessing 
wavelengths between 265-332 nm with a peak response at 290 nm). Media was    
removed from the cells, and cells were exposed to a dose of 10 J/m2 UVB.  
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3.2.3 Antibodies  
Antibodies directed against pSer435-ATR were previously generated against the 
peptide CPKRRR(pS)SSLNPS (Amsbio) as previously reported (Jarrett et al., 
2014). Commercially available antibodies included anti-CPD (Kamiya Biomedical), 
anti-ATR (Cell Signaling) anti-CREB (Cell Signaling), anti-pSer133-CREB (Cell 
Signaling), MITF (Cell Signaling), anti-Chk1 (Cell Signaling), and anti-pSer317-
Chk1 (Cell Signaling).  
3.2.4 pSer435-ATR Detection  
pSer435-ATR kinase assays were performed as previously described (Jarrett et 
al., 2015) using the biotinylated ATR peptide substrates CPKRRRLSSSLNPS 
(Genscript). Cells were plated in a 6 well well plate and treated with 0.1% ethanol 
vehicle or 10 µM forskolin for 1 hour prior to harvesting. 100 µM biotinylated ATR 
peptide substrate was added to a stepavidin-coated 96 well plate. 20 µg of whole 
cell lysate was added to the wells in 40 mM Tris-HCL (pH 7.5), 10 mM MgCl2, 1 
mM dithiothreitol (DTT), 100 µg/mL bovine serum albumin, and 10 µM ATP. The 
kinase reaction was performed at 30°C with gentile agitation. The reaction was 
terminated via the addition of 10 µL of 100 mM EDTA at 1 hour. PKA 
phosphorylation was measuring utilizing the anti-pSer435-ATR primary antibody. 
The primary antibody was conjugated to a horseradish peroxidase (HRP)-
conjugated anti-rabbit secondary antibody (Abcam) for 1 hour followed by the 
addition of QuantaBLu (Pierce). Fluorescence was detected by plate reader via 
excitation at 315 nM and emission at 400 nM. 
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3.2.5 DNA Isolation 
DNA was isolated using the Qiagen Kit per manufacturer’s instructions. Cultured 
cells were harvested and resuspended in 200 µL of PBS with 20 µL proteinase K. 
200 µL of buffer AL were added to the samples and vortexed. Cells were incubated 
at 56°C for 10 minutes. 200 µL of ethanol were added to the samples and vortexed. 
The mixture was pipetted into a DNeasy Mini spin column, centrifuged at 8000 rpm 
for 1 minute, and the flow through discarded. The column was placed in a collection 
tube, and 500 µL of buffer AW1 were added. The column was centrifuged at 8000 
rpm for 1 minute, the flow through discarded, the column placed in a new collection 
tube, and 500 µL of buffer AW2 were added. The column was centrifuged at 14,000 
rpm for 3 minutes, the flow through discarded, and the column placed in 1.5 mL 
microcentrifuge tube. 50 µL of AE buffer were added to the column, incubated for 
10 minutes at room temperature, and centrifuged at 8,000 rpm for 1 minute. DNA 
concentration was determined via Nanovue nanodrop (GE Healthcare). 
3.2.6 DNA Repair Kinetics  
 
Immuno slot blots were performed on whole cell lysates with 6,4 and CPD 
antibodies via standard methods (Mellon et al., 2002). 100 ng of DNA was diluted 
in 100 µL 1X Tris-ethylenediaminetetraacetic acid (EDTA) (TE) buffer to a 
concentration of 1 ng/µL. Samples were heated at 95 °C for 8 minutes and 
immediately placed on ice. Samples were diluted 1:1 with 100 µL of 20X saline-
sodium-phosphate-EDTA (SSPE) buffer for a final concentration of 0.5 ng/µL. 
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Nitrocellulose membrane (BioRad) was wetted in distilled water and washed in 6X 
SSPE. DNA was loaded onto nitrocellulose membrane on slot blot apparatus with 
vacuum turned off. After all samples were loaded, the vacuum was turned on until 
samples were pulled onto the membrane. Each well was then washed with 6X 
SSPE. Membrane was heated at 80°C for 1 hour in a vacuum oven.  After the 
membrane cooled, it was re-wetted in 6X SSPE and rinsed with Tris buffered saline 
(TBS) + 0.1% Tween (TBST) 2 times for 5 minutes each. Membrane was then 
blocked in 1X TBST with 5% w/v nonfat dry milk for 1 hour. Membrane was 
incubated with primary antibody at a dilution of 1:1000 in 1:1 solution of 1X TBST 
with 5% w/v nonfat dry milk overnight at room temperature. Membrane was 
washed for 5 minutes 4 times in 1X TBST. Membrane was incubated with HRP 
conjugated anti-mouse secondary antibody (Abcam) in 1X TBST with 5% w/v 
nonfat dry milk for 60 minutes. Membrane was washed with 1 X TBST for 5 minutes 
4 times. Immunodetection was performed via chemiluminescence utilizing the ECL 
Western Blotting Substrate (Thermo-Fisher). Immuno slot blots were scanned on 
the STORM scanner (GE Healthcare). Membranes were analyzed using ImageJ. 
 
3.2.7 Immunoblotting 
 
Immunoblots were performed on whole cell lystates in radioimmunoprecipitation 
assay (RIPA) buffer. Cells were lysed in RIPA buffer for 20 minutes at 4°C. Protein 
concentration was determined via Bradford protein assay (Life Technologies). 
Samples were diluted with 4X loading dye to a final concentration of 2X loading 
dye and DTT to a final concentration of 1 nM. 10-30 µg of protein were loaded onto 
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a 7-20% gradient sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) 
(BioRad). Gel was run at 200 V for 40 minutes in running buffer (25 mM Tris, 192 
mM glycine, 0.1% SDS). Polyvinylidene fluoride (PVDF) membrane (Millipore) was 
prepped prior to transfer. Membrane was wetted in 100% methanol for 30 seconds 
and equilibrated in transfer buffer (48 mM Tris, 39 mM glycine, 0.037% SDS, 15% 
methanol) for 20 minutes. Gel was equilibrated in transfer buffer for 5 minutes prior 
to transfer. Protein was transferred overnight at 100 mAmp at room temperature. 
Membrane was then blocked in 1:1 solution of Odyssey blocking buffer (Li-
Cor):PBS for 1 hour. Membrane was incubated with primary antibody in 1:1 
solution of Odyssey blocking buffer:PBS + 0.1% Tween (PBST) overnight at room 
temperature. Membrane was washed for five minutes four times in PBST. 
Membrane was incubated with anti-mouse (Molecular Probes) or anti-rabbit 
secondary antibody (Li-Cor) in 1:1 solution of Odyssey blocking buffer:PBST + 
0.01% SDS for 45 minutes. Membrane was washed with PBST for 5 minutes 4 
times. Membrane was washed in PBS for 30 seconds twice and scanned on the 
Odyssey (Li-Cor). Membranes were analyzed using ImageJ. 
3.2.8 mRNA Isolation  
Total RNA was harvested from cell culture using TRIzol (Life Technologies). Cells 
were harvested in 500 µl of TRIzol. Sample was incubated for five minutes at room 
temperature. 100 µL of chloroform were added to each sample, and each sample 
was shaken vigorously for 15 seconds. Sample was incubated for 2–3 minutes at 
room temperature. Sample was centrifuged at 12,000 × g for 15 minutes at 4°C. 
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RNA was isolated in the aqueous phase. RNA was precipitated with 250 µL of 
isopropanol. Sample was incubated at room temperature for 10 minutes and then 
centrifuged at 12,000 × g for 10 minutes at 4°C. Supernatant was removed. The 
RNA pellet was washed with 500 µL of ethanol and centrifuged at 7,500 × g for 5 
minutes at 4°C. Supernatant was removed and the RNA pellet was dissolved in 50 
µL RNase DNase free distilled water. RNA concentration was determined utilizing 
a Nanovue nanodrop (GE Healthcare). 
 
3.2.9 Reverse Transcriptase Polymerase Chain Reaction (RTPCR) 
 
1 µg of RNA was reverse transcribed to cDNA utilizing random hexamers and M-
MLV reverse transcriptase (Promega) in a Mastercycler epgradient thermocycler 
(Eppendorf International). cDNA was diluted 1:10 in RNase DNase free distilled 
water for use in quantitative real time polymerase chain reaction. 
 
3.2.10 Quantitative Real Time Polymerase Chain Reaction (qRTPCR) 
Quantitative real time real time polymerase chain reaction (qRTPCR) analysis was 
performed using an Applied Biosystems 7500 Real Time PCR System (Life 
Technologies) (10 ng cDNA/reaction) utilizing TATA-binding protein (TBP) as a 
reference gene. Primer sets for DCT were 5’- AACCAAAGCCACCAGTGTTC-3’ 
(right) and 5’-GGTTCCTTTCTTCCCTCCAG-3’ (left), MART1 were 5’-
ATAAGCAGGTGGAGCATTGG-3’ (right) and 5’- GCTCATCGGCTGTTGGTATT-
3’ (left), for Mitf were 5’-TACTTGGTGGGGTTTTCGAG- 3’ (right) and 5’-
AACTCATGCGTGAGCAGATG-3’ (left), for PMEL17 5’- 
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AACCAAAAGCCACCAGTGTTC-3’ (right) and 5’-GGTTCCTTTCTTCCCTCCAG-
3’, for TBP were 5 ́-CAGCGTGACTGTGAGTTGCT (left) and 5 -́ 
TGGTTCATGGGGAAAAACAT (right), and for TYR were 5 ́- 
TACGGCGTAATCCTGGAAAC (left) and 5 ́-ATTGTGCATGCTGCTTTGAG (right) 
(Integrated DNA Technologies).  
3.2.11 Statistics and Data Analysis  
One-way ANOVA with Tukey post-hoc test and two-way paired ANOVA analysis 
were performed using GraphPad Prism 5.0 (GraphPad Software). Data were 
considered statistically significant if p values were less than 0.05 from multiple 
independent experiments.  
3.3 Results 
3.3.1 MITF Inhibition Does Not Affect NER Kinetics 
In order to determine whether MITF plays a role in the acceleration of NER as 
mediated by ATR, we first addressed whether MITF affected phosphorylation of 
ATR. SK-MEL-2 melanoma cells or primary human melanocytes (PHMs) were pre-
treated with either scrambled or siRNA directed to MITF before incubation with 10 
µM forskolin, an activator of adenylyl cyclase. Accumulation of pSer435-ATR was 
measured by kinase assay as previously described (Jarrett et al., 2014). Treatment 
with forskolin caused a 6.0-fold and 4.0-fold induction of ATR phosphorylation of 
Ser435 in SK-MEL-2 (Figure 3.1 A) or PHMs (Figure 3.1 B) respectively, and levels 
of pSer435-ATR were not influenced by MITF knockdown (Figure 3.1 A, 3.1 B). d 
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Figure 3.1 MITF Inhibition Does Not Affect PKA Phosphorylation of ATR 
A-B) SK-MEL-2 melanoma cells (n = 3 independent experiments) (A) and 
PHMs (n = 4 independent experiments performed in 2 cell lines) (B) were 
treated with scrambled siRNA or siRNA directed to MITF prior to 
treatment with 10 µM forskolin. Whole cell lysates were collected at 1 
hour. pSer435-ATR levels were determined by kinase assay. MITF 
knockdown following treatment with siRNA directed to MITF is shown in 
inset (representative image of 3 independent experiments for SK-MEL-2 
melanoma cells (A) and 4 independent experiments for 2 PHM cell lines 
(B)). Graph in A is representative of 3 independent experiments 
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  performed in SK-MEL-2 melanoma cells. Graph in B is representative of 
4 independent experiments performed in 2 PHM cell lines. *p<0.05 
compared to control as determined by one-way ANOVA and Tukey post-
hoc test. Data are expressed as mean fold change over control ± SEM. 
Experiments were performed in collaboration with Dr. Stuart Jarrett, 
Ph.D. 
 71 
To determine directly whether MITF was required for MC1R-enhanced NER, we 
measured the effect of MITF inhibition on basal and cAMP-enhanced NER. SK-
MEL-2 cells were treated with 0.1% vehicle control or 10  µM forskolin for 30 
minutes prior to exposure to a sub-lethal dose (10 J/m2) of UVB radiation, and 
repair of CPDs was assessed at 0, 24, 48, and 72 hours. Treatment with forskolin 
significantly accelerated NER at 48 and 72 hours in SK-MEL-2 cells (Figure 3.2 A) 
and 24, 48, and 72 hours in PHMs (Figure 3.2 B) with and without the presence of 
MITF. We then directly compared the NER kinetics between cells with and without 
MITF knockdown. Neither basal repair kinetics (Figure 3.2 C, 3.2 E) nor forskolin 
enhanced repair (Figure 3.2 D, 3.2 F) were affected by MITF knockdown in either 
cells. These data suggest that MITF is dispensable for MC1R-induced NER 
enhancement.  
3.3.2 ATR is Not Required for PKA Phosphorylation of CREB 
We next determined whether ATR was required for other signaling events 
downstream of MC1R. Treatment of SK-MEL-2 cells (Figure 3.3 A, 3.3 B) or PHMs 
(Figure 3.3 C, 3.3 D) with 10 µM forskolin for 1 hour significantly increased PKA 
phosphorylation of CREB at Ser133 (2.4-fold induction for melanoma cell lines; 
2.6-fold induction for PHM). Inhibition of ATR kinase function via treatment with 10 
µM VE-821 did not prevent the forskolin induction of pSer133-CREB in either SK-
MEL-2 cells (Figure 3.3 A, 3.3 B) or PHMs (Figure 3.3 C, 3.3 D). pSer317-Chk1 
levels were decreased following treatment with VE-821 in UV-irradiated SK-MEL-
2 cells (Figure 3.3 E) and PHMs (Figure 3.3 F) confirming ATR kinase function was  
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Figure 3.2 MITF Inhibition Does Not Affect NER Kinetics 
A-F) Kinetics of CPDs were determined in SK-MEL-2 melanoma cells    
(n = 4 independent experiments) (A, C, D) and PHMs (n = 4 independent 
experiments performed in 2 cell lines) (B, E, F). Cells were treated with 
scrambled siRNA or siRNA directed to MITF. Cells were treated with 10 
µM forskolin for 30 minutes prior to treatment with 10 J/m2 UVB radiation. 
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  MITF knockdown following treatment with siRNA directed to MITF is 
shown in inset (representative image of 4 independent experiments for 
SK-MEL-2 melanoma cells (A) and 4 independent experiments 
performed in 2 PHM cell lines (B)). Graphs in A, C, and D are 
representative of 4 independent experiments performed in SK-MEL-2 
melanoma cells. Graphs in B, E, and F are representative of 4 
independent experiments performed in 2 PHM cell lines. *p < 0.05 as 
determined by two-way paired ANOVA (p<0.05). Data are expressed as 
mean %CPD remaining ± SEM. Experiments were performed in 
collaboration with Dr. Stuart Jarrett, PhD.  
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Figure 3.3 ATR Inhbition Does Not Affect PKA Phosphorylation of CREB 
A-D) SK-MEL-2 melanoma cells (n = 3 independent experiments) (A-B) 
and PHMs (n = 3 independent experiments performed in 2 PHM cell 
lines) (C-D) were treated with 10 µM forskolin, 10 µM VE821, or a 
combination of 10 µM forskolin and 10 µM VE-821. Whole cell lysates 
were collected 1 hour following treatment and immunoblotted for 
pSer133-CREB. Western blots displayed are representative images from 
3 independent experiments (A – SK-MEL-2; B – PHMs). Quantification 
of immunoblots for 3 independent experiments for SK-MEL-2 melanoma 
cells is represented in B. Quantification of immunoblots for 3 independent 
experiments performed in 2 PHM cell lines is represented in D. Values 
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  not sharing a common letter are significantly different as determined by 
one-way ANOVA and Tukey post hoc test (p<0.05). Data are expressed 
as mean fold change over control ± SEM. Data are expressed as mean 
fold change over control ± SEM. 
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Figure 3.4 VE-821 Inhibits ATR Kinase Function 
A-B) SK-MEL-2 melanoma cells (n = 3 independent experiments) (A) and 
PHMs (n = 4 independent experiments performed in 2 PHM cell lines) 
(B) were pre-treated with 0.1% vehicle control or 10 µM Ve-821 for 30 
minutes prior to treatment with 100 J/m2 UVB. Whole cell lysates were 
collected 1 hour following UV treatment and immunoblotted for pSer317-
Chk1. Western blots displayed are representative images from 3 
independent experiments (A – SK-MEL-2) and 4 independent 
experiments performed in 2 PHM cell lines (B – PHMs). 
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inhibited by VE-821. To further confirm ATR was not required for PKA 
phosphorylation of CREB, SK- MEL-2 melanoma cells were treated with either a 
scrambled control siRNA or siRNA directed to ATR prior to treatment with 10 µM 
forskolin. Forskolin resulted in a 1.6-fold induction of CREB phosphorylation in SK-
MEL-2 cells (Figure 3.5 A, 3.5 B). Similar to results seen with the inhibition of ATR 
kinase function by VE-821, ATR knockdown also did not prevent the 
phosphorylation of CREB (1.6-fold induction) (Figure 3.4 A, 3.4 B). These results 
suggest that ATR is not required for PKA-mediated CREB phosphorylation 
downstream of cAMP induction.  
3.3.3 ATR Kinase Function is Required for MITF Dependent Transcription 
To determine whether ATR is required for cAMP-mediated induction of genes 
required for melanin biosynthesis, we assessed the effect of ATR inhibition on 
cAMP-induced pigment enzyme gene expression. SK-MEL-2 cells were treated 
with 10 µM forskolin in the presence or absence of ATR inhibitor (10 µM VE-821) 
for 48 hours and gene expression assessed via quantitative real time PCR. 
Treatment with forskolin led to the induction of two pigment genes downstream of 
MITF (DCT [2.5-fold], TYR [1.3-fold]) (Figure 3.6 A). We also assessed the effect 
of forskolin on two additional MITF dependent genes, MART1 and PMEL17, which 
are present in melanosomes. Treatment with forskolin resulted in a 2.2-fold 
induction of MART1 gene expression and a 2.3-fold induction of PMEL17 gene 
expression (Figure 3.6 A). Although treatment with VE-821 did not affect the basal 
levels of the four genes (DCT [1.0-fold], MART1 [1.1-fold], PMEl17 [0.9-fold], TYR  
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Figure 3.5 ATR Knockdown Does Not Affect PKA Phosphorylation of 
CREB 
A-B) SK-MEL-2 melanoma cells (n = 3 independent experiments) were 
treated with scrambled siRNA or siRNA directed to ATR prior to treatment 
with 10 µM forskolin. Whole cell lysates were collected 1 hour following 
treatment and immunoblotted for pSer133-CREB. Western blot 
displayed is a representative image from 3 independent experiments. 
Quantification of immunoblots for 3 independent experiments for SK-
MEL-2 melanoma cells is represented in B. Quantification of 
immunoblots for 3 independent experiments performed in 2 PHM cell 
lines is represented in D. *p<0.05 compared to control as determined by 
one-way ANOVA and Tukey post-hoc test. Data are expressed as mean 
fold change over control ± SEM.  
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Figure 3.6 ATR Inhibition Prevents cAMP Induced Expression of Pigment 
Genes  
A) SK-MEL-2 (n = 3 independent experiments) melanoma cells were 
treated with 10 µM forskolin, 10 µM VE-821, or a combination of 10 µM 
forskolin and 10 µM VE-821. DCT, TYR, MART1, and PMEL17 gene 
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  expression was determined 48 hours following treatment. qRTPCR was 
performed in duplicate for each sample.  
B) SK-MEL-2 (n = 3 independent experiments) melanoma cells were 
treated with 10 µM forskolin, 10 µM VE-821, or a combination of 10 µM 
forskolin and 10 µM VE-821. Mitf gene expression was determined 48 
hours following treatment. qRTPCR was performed in duplicate for each 
sample.  
C) PHM (n = 4 independent experiments performed in 2 PHM cell lines) 
were treated with 10 µM forskolin, 10 µM VE-821, or a combination of 10 
µM forskolin and 10 µM VE-821. Mitf gene expression was determined 
48 hours following treatment. qRTPCR was performed in duplicate for 
each sample.  
*p<0.05 treatment compared to control as determined by one-way 
ANOVA and Tukey post-hoc test. #p<0.05 forskolin treatment compared 
to forskolin + VE-821 as determined by one-way ANOVA and Tukey post-
hoc test. Data are expressed as mean fold change over control ± SEM. 
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[1.0-fold]), inhibition of ATR kinase activity prevented the cAMP induction of all four 
genes (DCT [1.4-fold], MART1 [1.6-fold], PMEL17 [1.3-fold], TYR [1.0- fold]) 
(Figure 3.6 A).  
Because the induction of all four genes is dependent upon MITF activity (Levy et 
al., 2006), we tested whether VE-821 affected Mitf transcription in SK-MEL-2 cells 
and PHMs following treatment with 10 µM forskolin in the presence or absence of 
ATR inhibitor (10 µM VE- 821). Similar to the induction of MITF-dependent genes, 
treatment with forskolin resulted in a 1.4-fold induction of Mitf transcription 48 hours 
following treatment in SK-MEL-2 cells (Figure 3.6 B) and a 1.3-fold induction in 
PHMs (Figure 3.6 C). Inhibition of ATR with VE-821 did not affect basal MITF 
mRNA levels, however, it did prevent cAMP-mediated enhancement in Mitf 
expression in both melanoma (0.8-fold) (Figure 3.6 B) and PHM (0.9-fold) (Figure 
3.6 C) cell lines, suggesting that ATR is needed for cAMP-mediated up-regulation 
of Mitf expression.  
3.4 Conclusions/Discussion 
Herein we report that MITF does not appear to be required for MC1R-enhanced 
NER. MITF has the potential to affect MC1R-enhanced NER via multiple 
mechanisms. It functions as a transcription factor regulating genes involved in NER 
(Strub et al., 2011). In addition, MITF has also been shown to interact with and 
stabilize kinases, specifically the kinase Wnt (Rodriquez and Setaluri et al., 2014). 
It is possible, therefore, that MITF could assist in ATR stabilization indirectly 
affecting its kinase function. Despite these possibilities, MITF does not appear to 
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be necessary for pSer435-ATR accumulation, the critical molecular event on which 
MC1R-enhanced NER depends. Likewise, MITF inhibition had no impact on CPD 
clearance in the three cell lines tested, suggesting that MITF does not regulate 
basal NER or MC1R-enhanced genome maintenance.  
In contrast, our data suggest that ATR may be important to MITF and pigment 
enzyme induction downstream of MC1R signaling. Although inhibition of ATR 
kinase activity or ATR knockdown did not affect phosphorylation of CREB by PKA, 
inhibition of ATR kinase activity did prevent cAMP induction of Mitf gene 
transcription and transcription of MITF dependent pigment genes. Inhibition of ATR 
kinase activity did not lead to a significant alteration in basal Mitf gene levels or 
MITF dependent pigment genes, suggesting that ATR kinase activity is only 
necessary for activation of the adaptive pigmentation pathway and not for basal 
melanin synthesis. This observation is similar to the effect of ATR on NER kinetics 
in that ATR inhibition does not affect basal NER but completely abrogates cAMP 
accelerated NER (Jarrett et al., 2014). Because ATR did not prevent PKA 
phosphorylation of CREB, ATR appears to function downstream of PKA in the 
activation of the adaptive pigmentation pathway following cAMP stimulus and may 
be at the level of Mitf transcription. It is possible that the effect of ATR on Mitf 
transcription is due to an indirect or global effect, however, ATR to our knowledge 
has not yet been shown to have a role in the regulation of transcription of mRNA. 
It is also possible that the effect may due to direct modification of CREB or MITF 
by ATR. Future studies will determine whether the inhibition of the induction of 
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pigment genes is due to a direct or indirect effect, and our current data do not 
preclude either mechanism.  
 
In summary, we have identified an additional interaction between the induction of 
eumelanin synthesis and acceleration of NER downstream of MC1R. Although 
only eumelanin synthesis and not the acceleration of NER appears to be 
influenced by MITF function, both pathways appear to depend upon ATR kinase 
activity. These findings support a broad role for ATR in MC1R-mediated 
melanocyte UV adaptive responses. 
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________________________________________________________________________	
 
Chapter 4: The Effect of Rapamycin on the MC1R Dependent  
Signaling Pathways 
 
________________________________________________________________ 
 
4.1 Introduction 
 
Malignant cutaneous melanoma is a highly metastatic disease that causes 
approximately 75,000 deaths per year in the United States alone (Howlander et 
al., 2016). A majority of melanoma diagnoses result from mutations following 
exposure to carcinogenic ultraviolet (UV) radiation and damage of DNA bases 
(Brash et al., 1991; Hodis et al., 2012, Shain et al., 2015). Activation of the 
melanocortin 1 receptor (MC1R) signaling axis is a major innate defense 
mechanism to protect the skin from the harmful effects UV radiation by both 
preventing UV damage via the induction of eumelanin synthesis (Suzuki et al., 
1997) and accelerating the repair of UV induced DNA lesions (Abdel-Malek et al., 
2006; Hauser et al., 2006; Kadekaro et al., 2012; Jagirdar et al., 2013; Jarrett et 
al., 2014). Individuals with loss of function MC1R polymorphisms exhibit fair skin, 
have increased UV sensitivity, and a four fold increased risk of developing 
melanoma compared to the general population (Valverde et al., 1995). In addition 
to sustaining a larger degree of UV induced damage, individuals with a defective 
MC1R signaling axis also cannot repair their DNA as efficiently, and therefore 
acquire a greater number of mutations (Hauser et al., 2006; Jarrett et al., 2014).   
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Pharmacologic manipulation of the MC1R signaling axis in order to augment the 
protective signaling pathways is a major strategy to prevent UV induced melanoma 
(D’Orazio et al., 2006; Abdel-Malek et al., 2010; Khaled et al., 2010). Augmentation 
of the MC1R axis can occur either via direct activation of wild-type receptors 
utilizing MC1R ligand analogs (Abdel-Malek et al., 2010) or via augmentation of 
cAMP levels downstream of MC1R through activation of adenyly cylcase 
(forskolin) or inhibition of phosphodiesterase inhibitors (rolipram) (D’Orazio et al., 
2006; Khaled et al., 2010; Jarrett et al., 2014). In addition to activating the UV 
protective mechanisms, pharmacologic augmentation of the MC1R signaling axis 
has a potentially dangerous consequence, increased melanocyte proliferation 
(Suzuki et al., 1996; Kadekaro et al., 2003). Innately, the receptor has three 
endogenous ligands: the positive agonist α melanocyte stimulating hormone 
(αMSH) (Abdel-Malek et al., 2000), the negative agonist agouti signaling protein 
(ASIP) (Blanchard et al., 1995), and the neutral antagonist β-defensin 3 (βD3) 
(Candille et al., 2007), which regulate MC1R activity and function. In addition, like 
most G protein coupled receptors, activation of MC1R via ligand binding results in 
desensitization (Sanchez-Mas et al., 2005) and internalization (Sanchez-Laorden 
et al., 2007) of the receptor preventing the receptor from constant activation.  
Pharmacologic manipulation that bypasses the regulatory controls could result in 
unrestrained melanocyte proliferation increasing the potential for malignant 
transformation. 
 
The mechanistic target of rapamycin (mTOR) has been shown to play a role in 
proliferation in numerous physiological and pathological situations (Laplante and 
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Sabatini, 2012). mTOR is a member of the phosphatidyl inositol 3 kinase like 
kinase (PIKK) family (Lovejoy and Cortez, 2009), and MC1R and cAMP have been 
shown to affect the signaling of multiple members of the PIKK family including 
ataxia telangiectasia mutated (ATM) protein (Swope et al., 2014), ataxia 
telangiectasia mutated and Rad3 related (ATR) protein (Kadekaro et al., 2012; 
Jarrett et al., 2014; Swope et al., 2014), and DNA protein kinase (DNA-PK) 
(Kadekaro et al., 2012). In general, mTOR functions as a nutrient sensor, and 
activation of mTOR complex 1 (mTORC1) regulates a complex series of signaling 
events, including enhancing cell growth and proliferation (Laplante and Sabatini 
2012).  
 
In this paper we report that cAMP induced proliferation is sensitive to low doses of 
rapamycin, an inhibitor of mTORC1, and that rapamycin does not prevent cAMP 
induced eumelanin synthesis or the acceleration of DNA repair. Our findings 
suggest that it is possible via a combination of pharmacologic treatments to 
selectively enhance the MC1R protective pathways without the risk of uncontrolled 
proliferation. 
 
4.2 Methods 
 
4.2.1 Murine Model, Pigmentation, and UV Exposure 
 
Murine experimental protocols were approved by the Institutional Animal Care and 
Use Committee at the University of Kentucky. C57/BL/6JJ mice with a 
nonfunctional MC1R protein were crossed with K14-Scf transgenic animals (K14-
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Scf-MC1Re/e) (D’Orazio et al., 2006) to generate mice with humanized skin whose 
melanocytes were retained in the epidermis at the time of weaning. All murine 
experiments were performed in K14-Scf-MC1Re/e mice. 
 
For pigmentation experiments, mice were treated immediately after weaning. Mice 
were randomized into groups, and groups were sex matched. Mice were shaved, 
and the dorsal side of each mouse was divided into two non-overlapping regions. 
The anterior region was treated with a topical application of 70% ethanol 30% 
propylene glycol vehicle control. The posterior region was treated with a topical 
application of 10% forskolin in 70% ethanol 30% propylene glycol vehicle or 
combination of 10% forskolin and 1% rapamycin in 70% ethanol 30% propylene 
glycol vehicle. The dose of rapamycin used was similar to experiments performed 
in a mouse model of tuberous sclerosis utilizing a topical application of rapamycin 
(Rauktys et al., 2008). Each treatment was performed daily for five days with a 
two-day drug holiday for three weeks (22 days total). Skin reflective colorimetry 
was performed for each region of each mouse prior to treatment on day 1 and then 
prior to treatment on day 8, day 15, and day 22 after the two-day drug holiday. 
Colorimetry was performed utilizing a CR-400 Colorimeter (Minolta Corporation). 
Mice who had hair growth in the anagen phase were excluded from colorimetry 
measurements as the darkly pigmented hair could not be removed and would 
affect the measurements. The degree of pigmentation (darkness) was quantified 
as the measurement on the *L axis (white-black axis) of the CIE standard color 
axis and was determined by three independent measurements for each sample.  
 
 88 
For DNA repair experiments, mice ages ranged from 8 weeks – 14 weeks. Mice 
were randomized into groups, and groups were age and sexed matched. Mice 
were shaved, and the dorsal side of each mouse was treated with a topical 
application of 70% ethanol 30% propylene glycol vehicle, 10% forskolin in 70% 
ethanol 30% propylene glycol vehicle, or combination of 10% forskolin and 1% 
rapamycin in 70% ethanol 30% propylene glycol vehicle once a day for the time 
indicated. Mice were then treated with a one-time dose of 7.5 kJ/m2 UVB radiation 
via an overhead double bank of UVB lamps (UV Products). UV radiation was 
measured via a Model IL1400A handheld flash measurement photometer 
(International Light) with a UVB filter (assessing wavelengths between 265-332 nm 
with a peak response at 290 nm). 1 cm2 biopsies were taken at times indicated 
following UV radiation.  
 
4.2.2 Immunohistochemistry  
 
All immunohistochemistry preparation, skin processing, and staining was 
performed by the University of Kentucky Markey Cancer Center Biospecimen and 
Tissue Procurement Shared Resource Facility. Skin biopsies were fixed in 4% 
paraformaldehyde for 48 hours and subsequently placed in 70% ethanol. Biopsies 
were embedded in paraffin and sectioned onto slides. Slides were stained with 
Fontana Masson (Abcam) to assess melanin content. Slides were stained for Ki67 
(Abcam) to assess proliferation. For Ki67 staining, antigen retrieval was performed 
using citrate buffer (Dako).  
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4.2.3 Cell Lines, Pharmacologic Treatments, and siRNA 
 
Transformed SK-MEL-2 melanoma cells (ATCC) were cultured in Roswell Park 
Memorial Institute (RMPI) media (Life Technologies) with 10% fetal bovine serum. 
Forskolin (LC Laboratories), rapamycin (LC Laboratories), and H-89 
(Selleckchem) were utilized as indicated. siRNA targeted to raptor (Dharmacon), 
rictor (Dharmacon), and p70 (Dharmacon) were performed according to the 
manufacturer’s instructions.  
 
4.2.4 Antibodies 
 
Commercially available antibodies included anti-6,4 PP (Kamiya Biomedical), anti- 
CPD (Kamiya Biomedical), anti-pSer2448-mTOR (Cell Signaling), anti-mTOR 
(Cell Signaling), anti-pSer371-Akt (Cell Signaling), anti-Akt (Cell Signaling), anti-
raptor (Cell Signaling), anti-rictor (Cell Signaling), anti-p70S6K (Cell Signaling), 
anti-ATR (Cell Signaling), and anti-PKA substrate (Cell Signaling). 
 
4.2.5 In Vitro UV Exposure 
 
Cells were treated with 0.1% ethanol vehicle, 10 µM forskolin, 1 nM rapamycin, or 
a combination of 10 µM forskolin and 1 nM rapamycin as indicated for 1 hour prior 
to UV exposure. UV radiation was measured via a Model IL1400A handheld flash 
measurement photometer (International Light) with a UVB filter (assessing 
wavelengths between 265-332 nm with a peak response at 290 nm). Media was 
removed from the cells, and cells were exposed to a dose of 30 J/m2 UVB. 
 
 90 
4.2.6 Proliferation Studies 
 
Proliferation was assessed via cell number and cell viability. For cell number, cells 
were plated at a density of 5,000 cells/well in a 6 well plate. Cells were treated with 
0.1% ethanol vehicle, 10 µM forskolin, 1 nM rapamycin, or a combination of 10 µM 
forskolin and 1 nM rapamycin daily for 7 days. Cells were treated with 0.25% 
trypsin for 5 minutes at 32°C and harvested. Cells were resuspended in 500 µL of 
media. Cell count was manually determined ten times per sample. 
 
Cell viability was assessed via the tetrazolium 3-(4, 5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide (MTT) cell proliferation assay. Cells were plated at a 
density of 5,000 cells/well in a 24 well plate. Cells were treated with 0.1% ethanol 
vehicle, 10 µM forskolin, 1 nM rapamycin, or a combination of 10 µM forskolin and 
1 nM rapamycin daily for 4 days. The MTT substrate was prepared in phosphate 
buffered saline (pH 7.4) at a concentration of 1 mg/mL. Media was aspirated from 
the cells and 250 µL of MTT substrate was placed on each well. Cells were 
incubated for 20 minutes at 32°C. MTT solution was removed, and 250 µL of 
dimethyls sulfoxide (DMSO) was placed on each well to dissolve the MTT 
substrate. 100 µL of DMSO dissolved substrate was placed into a 96 well plate, 
and absorbance was assessed via plate reader at 560 nM excitation. 
 
4.2.7 DNA Isolation 
 
DNA was isolated using the Qiagen Kit per manufacturer’s instructions. For mouse 
studies, 25-50 mg of tissue were placed in 180 µL of ATL buffer with 20 µL of 
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proteinase K. Tissue was cut into small pieces and placed at 56°C overnight with 
regular vortexing until completely lysed. Cultured cells were harvested and 
resuspended in 200 µL of PBS with 20 µL proteinase K. 200 µL of buffer AL were 
added to both cells and tissue samples and vortexed. Cells were incubated at 56°C 
for 10 minutes. At this point, both tissue and cell culture samples were treated the 
same. 200 µL of ethanol were added to the samples and vortexed. The mixture 
was pipetted into a DNeasy Mini spin column and centrifuged at 8000 rpm for 1 
minute. The flow through was discarded, and the column was placed in a new 
collection tube. 500 µL of buffer AW1 was added to the column. The column was 
centrifuged at 8000 rpm for 1 minute. The flow through was discarded, and the 
column was placed in a new collection tube. 500 µL of buffer AW2 was added to 
the column. The column was centrifuged at 14,000 rpm for 3 minutes. The flow 
through was discarded, and the column was placed in 1.5 mL microcentrifuge tube. 
50 µL of AE buffer was placed on the column and incubated for 10 minutes at room 
temperature. The column was centrifuged at 8,000 rpm for 1 minute. DNA 
concentration was determined via a Nanovue nanodrop (GE Healthcare). 
 
4.2.8 DNA Repair Kinetics  
 
Immuno slot blots were performed on whole cell lysates with 6,4 PP and CPD 
antibodies via standard methods (Mellon et al., 2002). 100 ng of DNA was diluted 
in 100 µL 1X 1X Tris-ethylenediaminetetraacetic acid (EDTA) (TE) buffer to a 
concentration of 1 ng/µL. Samples were heated at 95 °C for 8 minutes and 
immediately placed on ice. Samples were diluted 1:1 with 100 µL of 20X saline-
 92 
sodium-phosphate-EDTA (SSPE) buffer for a final concentration of 0.5 ng/µL. 
Nitrocellulose membrane (Li-Cor) was wetted in distilled water and washed in 6X 
SSPE. DNA was loaded onto nitrocellulose membrane on slot blot apparatus with 
vacuum turned off. After all samples were loaded, the vacuum was turned on until 
samples were pulled onto the membrane. Each well was then washed with 6X 
SSPE. Membrane was heated at 80°C for 1 hour in a vacuum oven.  After the 
membrane cooled, it was re-wetted in 6X SSPE and rinsed with PBS + 0.1% 
Tween (PBST) 2 times for 5 minutes each. Membrane was then blocked in 1:1 
solution of Odyssey blocking buffer (Li-Cor):PBS for 1 hour. Membrane was 
incubated with primary antibody at a dilution of 1:1000 in 1:1 solution of Odyssey 
blocking buffer:PBST overnight at room temperature. Membrane was washed for 
five minutes four times in PBST. Membrane was incubated with anti-mouse 
secondary antibody (Licor) in 1:1 solution of Odyssey blocking buffer:PBST + 
0.01% sodium dodecyl sufate (SDS) for 45 minutes. Membrane was washed with 
PBST for 5 minutes 4 times. Membrane was washed in PBS for 30 seconds twice 
and scanned on the Odyssey (Li-Cor). Membranes were analyzed using ImageJ. 
 
4.2.9 Immunoprecipitation and Immunoblotting 
 
Immunoblots were performed on whole cell lystates in radioimmunoprecipitation 
assay (RIPA) buffer. Cells were lysed in RIPA buffer for 20 minutes at 4°C. Protein 
concentration was determined via Bradford protein assay (Life Technologies). 
Samples were diluted with 4X loading dye to a final concentration of 2X loading 
dye and dithiothreitol (DTT) to a final concentration of 1 nM. 10-30 µg of protein 
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were loaded onto a 7-20% gradient SDS-polyacrylamide gel (SDS-PAGE). Gel 
was run at 200 V for 40 minutes in running buffer (25 mM Tris, 192 mM glycine, 
0.1% SDS). Polyvinylidene fluoride (PVDF) membrane (Millipore) was prepped 
prior to transfer. Membrane was wetted in 100% methanol for 30 seconds and 
equilibrated in transfer buffer (48 mM Tris, 39 mM glycine, 0.037% SDS, 15% 
methanol) for 20 minutes. Gel was equilibrated in transfer buffer for 5 minutes prior 
to transfer. Protein was transferred overnight at 100 mAmp at room temperature. 
Membrane was then blocked in 1:1 solution of Odyssey blocking buffer:PBS for 1 
hour. Membrane was incubated with primary antibody in 1:1 solution of Odyssey 
blocking buffer:PBST overnight at room temperature. Membrane was washed for 
5 minutes 4 times in PBST. Membrane was incubated with anti-mouse or anti-
rabbit secondary antibody (Li-Cor) in 1:1 solution of Odyssey blocking buffer:PBST 
+ 0.01% sodium dodecyl sufate (SDS) for 45 minutes. Membrane was washed with 
PBST for 5 minutes 4 times. Membrane was washed in PBS for 30 seconds twice 
and scanned on the Odyssey (Li-Cor).  
 
Immunoprecipitations were performed in whole cell lysates in RIPA buffer. Whole 
cell lysates were incubated with 5 µg of antibody overnight at 4°C. 20% of the 
sample was removed for loading control immunoblot. 100 µL of beads were 
centrifuged at 5000 x g for 1 minute in a microcentrifuge, and the ethanol 
supernatant removed. The beads were washed three times in PBS to remove 
residual ethanol. Beads were dissolved in 100 µL of PBS and placed in the whole 
cell lysates. Samples rotated at 4°C for 2 hours. Samples were diluted with 4X 
loading dye to a final concentration of 2X and DTT to a final concentration of 1 nM. 
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Samples were centrifuged in a microcentrifuge for 1 minute prior to 
immunoblotting.  
 
4.2.10 RNA Isolation  
 
Total RNA was harvested from cell culture using TRIzol (Life Technologies). Cells 
were harvested in 500 µl of TRIzol. Sample was incubated for five minutes at room 
temperature. 100 µL of chloroform were added to each sample, and each sample 
was shaken vigorously for 15 seconds. Sample was incubated for 2–3 minutes at 
room temperature. Sample was centrifuged at 12,000 × g for 15 minutes at 4°C. 
RNA was isolated in the aqueous phase. RNA was precipitated with 250 µL of 
isopropanol. Sample was incubated at room temperature for 10 minutes and then 
centrifuged at 12,000 × g for 10 minutes at 4°C. Supernatant was removed. The 
RNA pellet was washed with 500 µL of ethanol and centrifuged at 7,500 × g for 5 
minutes at 4°C. Supernatant was removed, and the RNA pellet was dissolved in 
50 µL RNase DNase free dstilled water. RNA concentration was determined 
utilizing a Nanovue nanodrop (GE Healthcare). 
 
4.2.11 Reverse Transcriptase Polymerase Chain Reaction (RTPCR) 
 
1 µg of RNA was reverse transcribed to cDNA utilizing random hexamers and M-
MLV reverse transcriptase (Promega) in a Mastercycler epgradient thermocycler 
(Eppendorf International). cDNA was diluted 1:10 in RNase DNase free distilled 
water for use in quantitative real time polymerase chin reaction. 
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4.2.12 Quantitative Real Time Polymerase Chain Reaction (qRTPCR) 
 
Quantitative real time PCR (qRTPCR) analysis was performed using an Applied 
Biosystems 7500 Real Time PCR System (Life Technologies) (10 ng 
cDNA/reaction) utilizing TATA-binding protein (TBP) as a reference gene. Primer 
sets for DCT were 5’-AACCAAAGCCACCAGTGTTC-3’ (right) and 5’-
GGTTCCTTTCTTCCCTCCAG-3’ (left), MART1 were 5’-
ATAAGCAGGTGGAGCATTGG-3’ (right) and 5’-GCTCATCGGCTGTTGGTATT-
3’ (left), for PMEL17 5’-AACCAAAAGCCACCAGTGTTC-3’ (right) and 5’-
GGTTCCTTTCTTCCCTCCAG-3’, for TBP were 5´-
CAGCGTGACTGTGAGTTGCT (left) and 5´-TGGTTCATGGGGAAAAACAT 
(right), and for TYR were 5´-TACGGCGTAATCCTGGAAAC (left) and 5´-
ATTGTGCATGCTGCTTTGAG-3’ (right) (Integrated DNA Technologies). 
 
4.2.13 Statistics and Data Analysis  
 
Student’s T Test, two-way paired ANOVA analysis, and one-way ANOVA with 
Tukey post-hoc test were performed using GraphPad Prism 5.0 (GraphPad 
Software). Data were considered statistically significant if p values were less than 
0.05 from multiple independent experiments. 
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4.3 Results 
 
4.3.1 cAMP Enhances mTOR Phosphorylation in an mTORC1 Dependent 
Manner  
 
We first determined whether cAMP stimulus could affect mTOR signaling. 
Treatment of SK-MEL-2 cells with forskolin led to the phosphorylation of mTOR at 
Ser2448 over 6 hours suggesting potential activation of mTOR complex 1 
(mTORC1) (Figure 4.1 A and B). Treatment with forskolin, however, did not alter 
phosphorylation of Akt at Ser371 suggesting mTOR complex 2 (mTORC2) was not 
activated (Figure 4.1 C and D).  
 
Phosphorylation of mTOR at Ser2448 can occur in an mTOR kinase dependent or 
independent manner (Chiang and Abraham et al., 2005). To test whether the 
mTOR phosphorylation event was dependent upon mTORC1 activity, we 
assessed the role of the regulatory-associated protein of mammalian target of 
rapamycin (raptor) (a component of mTORC1) (Hara et al., 2002; Kim et al., 2003) 
on cAMP induced mTOR phosphorylation. SK-MEL-2 cells were treated with 
scrambled siRNA or siRNA directed to raptor prior to forskolin treatment for 6 
hours. Knock down of raptor prevented the forskolin induced pSer2448-mTOR 
(Figure 4.1 E and F) suggesting forskolin induced mTOR phosphorylation is 
dependent upon mTORC1 signaling. To confirm mTORC2 did not affect forskolin 
dependent mTOR phosphorylation, we looked at the role of rapamycin insensitive 
campanion of mTOR (rictor), a component of mTORC2 (Jacinto et al., 2004; 
Sarbassov et al., 2004). SK-MEL-2 cells were treated with scrambled siRNA or 	
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  Figure 4.1 cAMP Activates mTORC1 Independent of mTORC2 
A-B) SK-MEL-2 melanoma cells (n = 3 independent experiments) were 
treated with 0.1% ethanol vehicle or 10 µM forskolin. Whole cell lysates 
were collected at 0.5, 1, 2, and 6 hours following treatment and 
immunoblotted for pSer2448-mTOR. Western blots displayed are 
representative images from 3 independent experiments (A). 
Quantification of immunoblots for 3 independent experiments is 
represented in B. Data are expressed as mean fold change over control 
± SEM. 
C-D) SK-MEL-2 melanoma cells (n = 3 independent experiments) were 
treated with 0.1% ethanol vehicle or 10 µM forskolin. Whole cell lysates 
were collected at 0.5, 1, 2, and 6 hours following treatment and 
immunoblotted for pSer371-Akt. Western blots displayed are 
representative images from 3 independent experiments (C). 
Quantification of immunoblots for 3 independent experiments is 
represented in D.  Data are expressed as mean fold change over control 
± SEM. 
E-H) SK-MEL-2 melanoma cells (n=3) were treated with scrambled 
siRNA or siRNA directed to raptor (E-F) or rictor (G-H) prior to treatment 
with 10 µM forskolin. Whole cell lysates were collected 6 hours following 
treatment and immunoblotted for pSer2448-mTOR. Western blots 
displayed are representative images from 3 independent experiments (E, 
G). Quantification of immunoblots for 3 independent experiments  
melanoma cells is represented in B.  *p < 0.05 as determined by 
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  is represented in F and H.  *p < 0.05 as determined by Student’s T Test 
between the vehicle and forskolin treatment. Data are expressed as 
mean fold change over control ± SEM. 
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siRNA directed to rictor prior to forskolin treatment. Knock down of rictor did not 
affect the forskolin induced pSer2448-mTOR (Figure 4.1 G and H) suggesting 
forskolin induced mTOR phosphorylation is independent from mTORC2 signaling. 
 
4.3.2 cAMP Induced mTOR Phosphorylation is Dependent Upon p70S6K 
 
Phosphorylation of mTOR at Ser2448 can occur either via p70S6 kinase (p70S6K) 
(Chiang and Abraham et al., 2005) or protein kinase B (Akt) (Nave et al., 1999; 
Sekulic et al., 2000). Phosphorylation of mTOR at Ser2448 by p70S6K is 
dependent upon mTOR kinase function and and is rapamycin sensitive (Chiang 
and Abraham, 2005). In addition, p70S6K activity has been shown to be protein 
kinase A (PKA) dependent (Cass et al. 1999). Phosphorylation of mTOR at 
Ser2448 by Akt, however, is rapamycin insensitive (Chiang and Abraham, 2005), 
and Akt function and activation has been shown to be PKA independent (Cass et 
al., 1999). Because we observed that inhibition of mTORC1 prevented mTOR 
phosphorylation at Ser2448, we hypothesized that p70S6K was responsible for 
phosphorylating mTOR downstream of forskolin treatment.  
 
To determine whether the phosphorylation event was sensitive to rapamycin, SK-
MEL-2 cells were treated with 10 µM forskolin, 1 nM rapamycin, or a combination 
of 10 µM forskolin and 1 nM rapamycin for 6 hours. Treatment with forskolin 
resulted in an increase in mTOR phosphorylation at Ser2448. Treatment with 
rapamycin decreased basal pSer2448-mTOR and prevented the phosphorylation 
of mTOR at Ser2448 downstream of forskolin (Figure 2.2 A and B). We next tested 
whether pSer2448-mTOR was dependent upon PKA signaling. SK-MEL-2 cells  
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Figure 4.2 p70S6K Phosphorylates mTOR at Ser2448 Downstream of 
cAMP  
A-B) SK-MEL-2 melanoma cells (n = 3 independent experiments) were 
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  treated with 0.1% ethanol vehicle, 10 µM forskolin, 1 nM rapamycin, or a 
combination of 10 µM forskolin and 1 nM rapamycin. Whole cell lysates 
were collected 6 hours following treatment and immunoblotted for 
pSer2448-mTOR. Western blots displayed are representative images 
from 3 independent experiments (A). Quantification of immunoblots for 3 
independent experiments is represented in B. Values not sharing a 
common letter are significantly different as determined by one-way 
ANOVA and Tukey post hoc test (p<0.05). Data are expressed as mean 
fold change over control ± SEM. 
C-D) SK-MEL-2 melanoma cells (n = 3 independent experiments) were 
treated with 0.1% ethanol or DMSO vehicle, 10 µM forskolin, 10 µM H89, 
or a combination of 10 µM forskolin and 10 µM H89. Whole cell lysates 
were collected 6 hours following treatment and immunoblotted for 
pSer2448-mTOR. Western blots displayed are representative images 
from 3 independent experiments (C). Quantification of immunoblots for 3 
independent experiments is represented in D. Values not sharing a 
common letter are significantly different as determined by one-way 
ANOVA and Tukey post hoc test (p<0.05). Data are expressed as mean 
fold change over control ± SEM. 
E-F SK-MEL-2 melanoma cells (n = 3 independent experiments) were 
treated with scrambled siRNA or siRNA directed to p70S6K prior to 
treatment with 10 µM forskolin. Whole cell lysates were collected 6 hours 
following treatment and immunoblotted for pSer2448-mTOR. 
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  Western blots displayed are representative images from 3 independent 
experiments (E). Quantification of immunoblots for 3 independent 
experiments is represented in F. *p < 0.05 as determined by Student’s T 
Test between the vehicle and forskolin treatment. Data are expressed as 
mean fold change over control ± SEM. 
G-J Coimmunoprecipitation experiments were performed in SK-MEL-2 
melanoma cells (n=3) with anti-Akt (G), anti-p70S6K (H), anti-mTOR (I), 
and anti-ATR (J) and immunoblotted for anti-PKA substrate. Input 
represents 10% of total lysates. 
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were treated with 10 µM forskolin,10 µM H-89, an inhibitor of PKA signaling, or a 
combination of 10 µM forskolin and 10 µM H-89 for 6 hours. Treatment with H-89 
decreased basal pSer2448-mTOR and prevented the forskolin induced pSer2448-
mTOR (Figure 2.2 C and D).  
 
Finally, we directly tested whether p70S6K was responsible for mTOR 
phosphorylation downstream of cAMP stimulus. SK-MEL-2 melanoma cells were 
treated with scrambled siRNA or siRNA directed to p70S6K prior to treatment with  
forskolin for 6 hours. Knockdown of p70S6K prevented the phosphorylation of 
mTOR at Ser2448 after forskolin treatment (Figure 2.2 E and F) confirming that 
p70S6K phosphorylates mTOR downstream of cAMP accumulation. 
 
Because phosphorylation of mTOR by p70S6K was PKA dependent downstream 
of cAMP, we tested whether PKA could directly phosphorylate components of the 
mTOR signaling pathway, specifically mTOR, Akt, and p70S6K. SK-MEL-2 
melanoma cells were treated with forskolin for 1 hour. An immunoprecipitation was 
performed on whole cell lysates for mTOR, Akt, and p70S6K and immunoblotted 
for the PKA substrate antibody that recognizes sites that have undergone PKA 
phosphorylation. As a positive control, we also assessed the phosphorylation of 
ATR following cAMP stimulus as we previously reported it is phosphorylated by 
PKA (Jarrett et al., 2014). PKA did not directly phosphorylate Akt (Figure 4.2 G), 
p70S6K (Figure 4.2 H), or mTOR (Figure 4.2 I) but did phosphorylate ATR (Figure 
4.2 J) following cAMP stimulus suggesting that there is an additional protein which 
is activated by cAMP that regulates mTORC1 activity.   
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4.3.3 cAMP Induced Proliferation is Rapamycin Sensitive 
 
Given that mTOR is known to affect proliferation and that cAMP stimulus altered 
mTOR activity in a rapamycin sensitive manner, we tested the effect of rapamycin 
on cAMP induced proliferation in SK-MEL-2 melanoma cells. Treatment of cells 
with forskolin for 7 days led to an increase in proliferation as assessed by cell 
number. Treatment with a low dose of rapamycin (1 nM) led to a slight decrease 
in basal proliferation and prevented the forskolin induced proliferation (Figure 4.3 
A). We then confirmed the effect of rapamycin on forskolin induced proliferation 
via MTT. Forskolin led to an increase in cell viability in SK-MEL-2 cells after 4 days 
of treatment. Similar to the effects seen with cell number, treatment with rapamycin 
caused a slight decrease in basal cell viability and prevented the forskolin induced 
proliferation (Figure 4.3 B) suggesting that cAMP induced proliferation in 
melanocytes is dependent upon mTOR activity.  
 
4.3.4 MC1R Induced UV Protective Pathways Are Rapamycin Insensitive In 
Vitro 
 
To determine whether it would be possible to selectively augment the MC1R 
protective pathways without the risk of proliferation, we assessed whether 
simultaneous treatment of rapamycin and forskolin affected the induction of 
eumelanin synthesis and acceleration of NER in vitro. We first determined the 
effect of rapamycin on the induction of microphthalmia-associated transcription 
factor (MITF) dependent genes involved in pigmentation. SK-MEL-2 melanoma 
cells were treated with 10 µM forskolin, 1 nM rapamycin, or a combination of 10  
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Figure 4.3 cAMP Induced Proliferation is Rapamycin Sensitive 
A) SK-MEL-2 melanoma cells (n = 3 independent experiments) were 
treated with 0.1% ethanol vehicle, 10 µM forskolin, 1 nM rapamycin, or a 
combination of 10 µM forskolin and 1 nM rapamycin for 7 days. 
Proliferation was assessed by cell count.  
B) SK-MEL-2 melanoma cells (n = 3 independent experiments) were 
treated with ethanol vehicle, 10 µM forskolin, 1 nM rapamycin, or a 
combination of 10 µM forskolin and 1 nM rapamycin for 4 days. Cell 
viability was assessed via MTT reaction.  
Values not sharing a common letter are significantly different as 
determined by one-way ANOVA and Tukey post hoc test (p<0.05). Data 
are expressed as mean fold change over control ± SEM. 
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µM forskolin and 1 nM rapamycin for 48 hours. Treatment with forskolin resulted 
in an increase in expression for four MITF dependent genes: DCT, MART1, 
PMEL17, and TYR. Treatment with rapamycin did not affect basal gene 
transcription. It also did not prevent the forskolin dependent induction of MITF 
dependent genes, and for MART1 and TYR, the combination of forskolin and 
rapamycin resulted in enhanced gene transcription above forskolin treatment 
alone (Figure 4.4 A).  
 
To determine whether rapamycin prevented forskolin enhanced NER, SK-MEL-2 
cells were treated with 10 µM forskolin, 1 nM rapamycin, or a combination of 10 
µM forskolin and 1 nM rapamycin for 1 hour prior to treatment with 30 J/m2 UVB 
radiation. Clearance of cyclobutanedipyrimidine dimers (CPDs) was assessed at 
0, 24, and 48 hours following UV treatment. Treatment with forskolin significantly 
accelerated repair of CPDs at 24 and 48 hours, and rapamycin treatment alone 
did not affect basal NER kinetics, nor did it inhibit forskolin accelerated repair 
(Figure 4.4 B). These data suggest it may be possible to utilize a combination of 
pharmacologic drugs to activate MC1R pathways and prevent the induction of 
proliferation. 
 
4.3.5 Selective Activation of MC1R Protective Pathways In Vivo  
 
In order to test whether it is possible to selectively augment the MC1R protective 
pathways in vivo, we utilized a murine model with humanized skin due to 
expression of a K14-Scf transgene with a non-functional MC1R protein (K14-Scf-
MC1Re/e). The expression of Scf results in melanocyte retention in the epidermis.  
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Figure 4.4 Rapamycin Does Not Prevent cAMP Induced Eumelanin 
Synthesis or Acceleration of NER In Vitro 
A) SK-MEL-2 (n = 3 independent experiments) melanoma cells were 
treated with 0.1% ethanol vehicle, 10 µM forskolin, 10 nM rapamycin , or 
a combination of 10 µM forskolin and 1 nM rapamycin. DCT, TYR, 
MART1, and PMEL17 gene expression was determined 48 hours 
Time After UV Treatment 
(Hr) 
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  following treatment. qRTPCR was performed in duplicate for each 
sample. Values not sharing a common letter are significantly different as 
determined by one-way ANOVA and Tukey post hoc test (p<0.05). Data 
are expressed as mean fold change over control ± SEM.  
B) Kinetics of CPDs were determined in SK-MEL-2 melanoma cells (n = 
5 independent experiments). Cells were treated with 0.1% ethanol 
vehicle, 10 µM forskolin, 10 nM rapamycin , or a combination of 10 µM 
forskolin and 1 nM rapamycin for 1 hour prior to treatment with 30 J/m2 
UVB radiation. Kinetics were assessed at 0, 24, and 48 hours following 
UV exposure. Values not sharing a common letter are significantly 
different as determined by two-way paired ANOVA (p<0.05). Data are 
expressed as mean percent CPD remaining ± SEM.  
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Previous studies have demonstrated that topical treatment of the K14-Scf-MC1Re/e 
mice with forskolin can induce tanning of the skin downstream of MC1R (D’Orazio 
et al., 2006) suggesting that these mice are a useful model to study augmentation 
of the MC1R pathway. We first tested whether whether rapamycin affected cAMP 
induced proliferation in an in vivo setting. Each mouse was shaved, and the dorsal 
region of the mouse was divided into to two non-overlapping regions. The anterior 
dorsal region was treated with a 70% propylene rapamycin in 70% propylene glycol 
30% ethanol, and the posterior dorsal region was treated with 10% forskolin in 70% 
propylene glycol 30% ethanol vehicle or 10% forskolin + 1% rapamycin in 70% 
propylene glycol 30% ethanol vehicle for three weeks. Skin biopsies were taken at 
day 22 and processed for immunohistochemistry. Treatment with forskolin led to 
an increase in epidermal cell proliferation as assessed by staining for Ki67 which 
was prevented by simultaneous treatment with rapamycin (Figure 4.5 A). 
 
We next assessed whether rapamycin affected forskolin induced eumelanin 
synthesis in vivo. Each mouse was shaved, and the dorsal region of the mouse 
was divided into to non-overlapping regions. The anterior dorsal region was treated 
with a 70% propylene glycol 30% ethanol vehicle control, and the posterior dorsal 
region was treated with 10% forskolin in 70% propylene glycol 30% ethanol vehicle 
or 10% forskolin + 1% rapamycin in 70% propylene glycol 30% ethanol vehicle for 
three weeks. Topical application of forksolin lead to an induction of melanin 
synthesis over the three weeks as measured by reflective colorimetry (Figure 4.5 
B). Simultaneous treatment with rapamycin did not prevent forksolin induction of 
pigment over three weeks (Figure 4.5 B). To confirm rapamycin did not affect  
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Figure 4.5 Rapamycin Prevents Proliferation But Does Not Affect cAMP 
Induced Eumelanin Synthesis In Vivo 
A-C) K14-Scf MC1R e/e mice (n=6 per group) were treated for 3 weeks 
with a topical application of 70% ethanol 30% propylene glycol, 10% 
Time After Initial Treatment 
(Week) 
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  forskolin, or a combination of 10% forskolin and 1% rapamycin.  
(A) Histological analysis of mouse skin samples following 3 weeks of 
topical forskolin. Tissues were stained for Ki67 to assess proliferation. 
Images presented are representative of 6 independent experiments.  
(B) Degree of skin pigmentation was calculated via *L score vehicle - *L 
score treatment for each mouse (n=3-6 per time point). Data are 
expressed as mean ± SEM.  
(C) Histological analysis of mouse skin samples following 3 weeks of 
topical forskolin. Tissues were stained via the Fontana Masson stain to 
assess eumelanin production. Images presented are representative of 6 
independent experiments.  
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pigment induction, skin biopsies were obtained at three weeks following treatment 
and processed for immunohistochemistry. Samples were stained for melanin via 
the Fontana Masson (FM) stain. Treatment with forskolin led to an increase in FM 
stain, and simultaneous treatment with rapamycin did not prevent the induction 
(Figure 4.5 C). 
 
In order to determine whether rapamycin affected cAMP induced acceleration of 
NER kinetics, we first further characterized the NER kinetics in the K14-Scf-
MC1Re/e mice. We previously reported that treatment with forskolin for five days 
accelerated repair of CPDs in the K14-Scf-MC1Re/e mice, however, we did not 
determine the effect on pyrimidine 6,4 pyrimidone photoproducts (6,4 PPs) (Jarrett 
et al., 2014). We characterized the innate repair kinetics of 6,4 PPs and CPDs in 
the K14-Scf-MC1Re/e mouse model. Repair of 6,4 PPs occurred faster than CPDs 
and were nearly 100% removed by 72 hours (Figure 4.6 A). In contrast, at 72 
hours, only 70% of CPDs had been repaired (Figure 4.6 B). 
 
Previous in vitro and in vivo studies have demonstrated that MC1R activation is 
required prior to exposure to UV radiation in order to accelerate NER. No study, 
however, has tested the duration of treatment that is required prior to UV exposure 
to accelerate NER in an in vivo setting. We next tested how far in advance the 
mice required topical forskolin pretreatment in order for cAMP to accelerate NER. 
Mice were pre-treated once a day with forskolin for 3 days, 1 day, or 1 hour prior 
to exposure to 7.5 kJ/m2 UVB radiation. Repair of 6,4 PPs and CPDs was 
assessed at 0, 16, and 24 hours following UV exposure. Pretreatment with topical  
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Figure 4.6 cAMP Enhanced NER Kinetics In Vivo 
A-B) Basal repair kinetics of 6,4 PPs (A) (n = 3 independent experiments) 
and CPDs (B) (n = 3 indepndent experiments) in K14-Scf MC1R e/e mice. 
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Data are expressed as mean percent 6,4 PP or CPD remaining ± SEM.  
C-H) K14-Scf MC1R e/e mice (n=3 per group) were pre-treated for 1 hour 
(C, D), 1 day (E, F), or 3 days (G, H) with a topical application of 70% 
ethanol 30% propylene glycol or 10% forskolin in 70% ethanol 30% 
propylene glycol prior to exposure to 7.5 kJ/m2 UVB. Kinetics of repair of 
6,4 PPs (C, E, G) and CPDs (D, F, H) were assessed at 0, 16, and 24 
hours following UV exposure. *p<0.05 forskolin compared to vehicle as 
determined by two-way ANOVA. Data are expressed as mean percent 
6,4 PP or CPD remaining ± SEM.  
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forskolin for 1 hour did not accelerate NER kinetics for either 6,4 PPs or CPDs 
(Figure 4.6 C, 4.6 D). Pretreatment with topical forskolin for 1 day accelerated the 
NER kinetics for 6,4 PPs at 16 and 24 hours (Figure 4.6 E), however, there was 
no benefit seen for CPDs (Figure 4.6 F). Pretreatment with topical forskolin for 3 
days accelerated NER in both 6,4 PPs (16 hours) (Figure 4.6 G) and CPDs (24 
hours) (Figure 4.6 H). Because CPDs have increased mutagenicity compared to 
6,4 PPs (You Y et al., 2001), all subsequent DNA repair experiments were 
performed using a 3 day forskolin pre-treatment. 
 
To determine whether rapamycin affected the acceleration of NER following 
treatment with forskolin, mice were shaved and treated with 70% propylene glycol 
30% ethanol vehicle, 10 % forskolin in 70% propylene glycol 30% ethanol vehicle, 
or a combination of 10% forskolin and 1% rapamycin in 70% propylene glycol 30% 
ethanol vehicle for three days once a day prior to exposure to 7.5 kJ/m2 UVB 
radiation. Repair of 6,4 PP and CPDs was assessed at 0, 16, and 24 hours 
following UV exposure similar to previous experiments. Treatment with forskolin 
significantly accelerated repair of 6,4 PP at 16 and 24 hours (Figure 4.7 A) and 
CPDs at 24 hours (Figure 4.7 B), and simultaneous treatment with rapamycin did 
not prevent the forskolin acceleration of repair (Figure 4.7 A and B). These data 
further suggest it may be possible to activate the induction of eumelanin synthesis 
and accelerate NER independent of cAMP induced proliferation.  
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Figure 4.7 Rapamycin Does Not Prevent cAMP Enhanced NER Kinetics In 
Vivo 
A-B) K14-Scf MC1R e/e mice (n=5 per group) were pre-treated for 3 days 
with a topical application of 70% ethanol 30% propylene glycol, 10% 
forskolin or a combination of 10% forskolin and 1 % rapamycin prior to 
exposure to 7.5 kJ/m2 UVB. Kinetics of repair of 6,4 PPs (A) and CPDs 
(B) were assessed at 0, 16, and 24 hours following UV exposure. *p<0.05 
forskolin compared to vehicle as determined by two-way ANOVA. Data 
are expressed as mean percent 6,4 PP or CPD remaining ± SEM.  
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4.4 Conclusions/Discussion 
 
 
Activation of the MC1R signaling axis represents a major innate UV protective 
mechanism to prevent and repair UV induced DNA damage. Pharmacologic 
manipulation of MC1R signaling is a potential method to enhance the physiologic 
protective pathways in individuals with both defective and intact MC1R signaling 
to prevent UV induced skin cancers (Hauser et al., 2006; D’Orazio et al., 2006; 
Khaled et al., 2010; Jarrett et al., 2014). Unregulated activation of cAMP signaling, 
however, can lead to melanocyte proliferation with an increased potential for 
malignant transformation (Suzuki et al., 1996; Kadekaro et al., 2003). In order for 
pharmacologic manipulation of MC1R signaling to be a viable translational option, 
it must be possible to selectively augment the two protective pathways without the 
risk for proliferation. Herein we report that cAMP leads to activation of mTORC1, 
that proliferation downstream of cAMP is sensitive to rapamycin in vitro and in vivo, 
and that rapamycin treatment did not affect cAMP induced eumelanin synthesis or 
enhancement of NER kinetics in vitro or in vivo.  
 
We report that that the proliferation downstream of cAMP is a result of mTOR 
signaling. cAMP accumulation leads to the activation of mTORC1 downstream of 
PKA as evident by phosphorylation of mTOR at Ser2448 by p70S6K in an 
mTORC1 dependent manner. Inhibition of mTORC2 did not affect cAMP induced 
mTOR phosphorylation, and forskolin did not affect phosphorylation of Akt at 
Ser371 suggesting cAMP signals in an mTORC2 independent manner. PKA did 
not directly phosphorylate mTOR, Akt, or p70S6K suggesting PKA activates an 
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additional regulatory component upstream of mTORC1. The activation of the 
mTORC1 signaling pathway is complex and a result of numerous pathways 
converging at the regulation of the mTORC1 inhibitors tuberous sclerosis 1 and 
tuberin (TSC1/TSC2) (Laplante and Sabatini, 2012). One of the major pathways 
which regulates TSC1/TSC2 activity is the phopshoinositide 3 kinase (PI3K)/Akt 
pathway. Activation of Akt downstream of PI3K dishinibits mTORC1 via an 
inhibition of TSC1/TSC2 (Manning et al., 2002). Recent data reports that MC1R 
activation leads to an increase in the PI3K inhibitor phosphatase and tensin 
homolog (PTEN) function and a subsequent inhibition of PI3K/Akt signaling (Cao 
et al., 2013). Increased PTEN levels would theoretically have an effect of 
decreasing mTOR signaling due to inhibition of the PI3K/Akt cascade. We 
hypothesize, therefore, that MC1R activation of mTOR occurs via a different 
mechanism.  
 
Our data suggest that activation of proliferation can be independently inhibited 
while maintaining the UV protective pathways downstream of cAMP. We 
demonstrated that through a combination of pharmacologic drugs to activate cAMP 
signaling downstream of MC1R (forskolin) and prevent cAMP induced proliferation 
(rapamycin) it was possible to selectively augment the cAMP dependent UV 
protective pathways. Treatment with rapamycin did not prevent forskolin induction 
of eumelanin synthesis or acceleration of NER, and in fact, the combination of 
forskolin and rapamycin led to an increase in pigment enzyme expression above 
that of forskolin alone in vitro. A similar effect was not seen in vivo, and it is possible 
that the combination of forskolin and rapamycin did not further augment protein 
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levels of pigment associated enzymes. It is possible, however, that higher 
concentrations of rapamycin could promote pigment synthesis in the mouse model, 
or that UV exposure could be required for an increase in pigment production 
downstream of rapamycin. Tacrolimus, a macrolide immunosuppressant similar to 
rapamycin, has been shown to increase the eumelanin levels in melanocytes and, 
following UVB exposure, facilitate the transfer of melanosomes from melanocytes 
to keratinocytes (Jung et al., 2016). Topical tacrolimus has been used to promote 
repigmentation in patients with vitiligo. Both rapamycin and tacrolimus bind to the 
FK-binding protein 12 (FKBP12), however, the rapamycin-FKBP12 complex 
inhibits mTOR while the tacrolimus-FKBP12 complex inhibits calcinuerin. Despite 
their differing mechanisms of action, both tacrolimus and rapamycin function to 
decrease IL-2 levels. It is possible that either the effect on cytokine signaling or the 
complex with between tacrolimus or rapamycin and FKBP12 could affect 
pigmentation. 
 
In addition to demonstrating that proliferation was independently regulated from 
pigmentation and NER, we determined that a 3-day pretreatment was required in 
vivo to accelerate NER kinetics of CPDs. The acceleration of 6,4 PPs, however, 
occurred after both the 1-day and 3-day pretreatment with forskolin. We previously 
demonstrated that acceleration of NER downstream of cAMP is dependent upon 
ATR phosphorylation by PKA and the subsequent recruitment of XPA to sites of 
photodamage by ATR (Jarrett et al., 2014). 6,4 PPs cause a larger distortion to the 
DNA helix and are more easily recognized and repaired. It is possible, therefore, 
that the ATR/XPA complex preferentially recognize sites of 6,4 PPs before CPDs. 
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Because CPDs are more mutagenic than 6,4 PPs, however, it would be necessary 
to accelerate their repair to see a therapeutic benefit. 
 
In summary, our data have direct translational relevance. We have determined in 
mice that a minimum of 3-day forskolin pretreatment prior to UV exposure is 
required for the acceleration of NER, suggesting a multi-day treatment will also be 
required in humans. In addition, the combination treatment of forskolin and 
rapamycin demonstrates a proof of principle that it is possible to selectively 
augment the UV protective pathways downstream of MC1R without the risk of 
proliferation suggesting augmentation of the MC1R pathway may be a viable 
translational option to prevent melanoma development.  
	
	
	
	
	
	
	
	
 
 
 
 
 
Copyright © Erin Marissa Wolf Horrell 2016 
 122 
________________________________________________________________ 
 
 
Chapter 5: Overall Conclusions, Limitations, Future Studies, and Summary 
 
________________________________________________________________ 
 
 
5.1 Overall Conclusions 
 
The melanocortin 1 receptor (MC1R) signaling axis is a major innate defense 
mechanism to protect against ultraviolet (UV) radiation induced skin cancer, 
particularly melanoma. Activation of the receptor by its positive agonist, α 
melanocyte stimulating hormone (αMSH), leads to the induction of eumelanin 
synthesis (Suzuki et al., 1997) (Figure 1.7) and the acceleration of nucleotide 
excision repair (NER) (Hauser et al., 2006; Kadekaro et al., 2012; Jagirdar et al., 
2013) (Figure 1.4, Figure 1.8) to prevent and repair UV induced DNA damage 
respectively. Individuals with loss-of-function mutations in MC1R typically have fair 
skin, exhibit increased sun sensitivity, and are at an increased risk for developing 
UV induced melanoma due to loss of the UV protective pathways (Valverde et al., 
1995). Pharmacologic manipulation of MC1R signaling is a potential mechanism 
to augment the UV protective signaling pathways in individuals with loss-of-
function mutations in MC1R (Abdel-Malek et al., 2006; D’Orazio et al., 2006; 
Khaled  et al., 2010; Jarrett et al., 2014). In addition to promoting UV protective 
pathways, however, MC1R signaling also promotes melanocyte proliferation 
(Suzuki et al., 1996; Kadekaro et al., 2003). Unregulated MC1R activation, 
therefore, could lead to uncontrolled melanocyte proliferation increasing the 
potential for malignant transformation. The overall goal of this dissertation is to 
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further elucidate the complexities of MC1R signaling, specifically to assess the 
interdependence of the pigmentation, NER, and proliferation pathways to 
determine whether any one pathway could be selectively augmented or inhibited 
in a translationally relevant manner. 
 
MC1R signaling is controlled via three endogenous ligands, the positive agonist 
αMSH (Abdel-Malek et al., 2000), the neutral antagonist β-defensin 3 (βD3) 
(Candille et al., 2007), and the negative agonist agouti signaling protein (ASIP) 
(Blanchard et al., 1995). Understanding the regulation of these ligands following 
UV exposure is important to better understand how MC1R signaling is 
physiologically controlled. The ligands function in a competitive manner as binding 
of MC1R to any ligand is mutually exclusive (Ollmann et al., 1998; Swope et al., 
2012; Nix et al., 2013). Therefore, binding of ASIP (Blanchard et al., 1995) or βD3 
(Candille et al., 2007) to MC1R prevents activation of MC1R via αMSH.  
 
Although the regulation of αMSH expression is well characterized and known to 
be dependent upon UV damage (Cui et al., 2007), the regulation of βD3, 
specifically following UV exposure, is not entirely understood. We previously 
demonstrated that binding of βD3 to MC1R prevented αMSH induced acceleration 
of NER in a dose dependent manner (Jarrett et al. 2015)  suggesting that increased 
levels of βD3 in the skin would negatively correlate with αMSH induced MC1R 
signaling. It is therefore important to understand how βD3 expression is regulated 
in the skin. In Chapter 2, we demonstrated that UV radiation of ex vivo human 
whole skin explants was not sufficient to cause an increase in βD3 expression, 
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however, an in vivo study utilizing human volunteers, demonstrated that βD3 
expression was induced following UV radiation (Glaser et al., 2009). Taken 
together, these studies suggest that βD3 induction following UV is not dependent 
upon DNA damage as documented for αMSH, and that there are additional factors 
regulating βD3 expression. βD3 is canonically studied for its role in the immune 
response and has been shown to be induced by multiple cytokines including tumor 
necrosis factor α (TNFα) and interleukin-1β (IL-1β) (Harder et al., 2001) during 
pathological situations of sustained inflammation such as wound healing (Kesting 
et al., 2010). UV induced sunburns also lead to a high degree of inflammation and 
similar cytokine induction as wound healing, including TNFα (Schwarz et al., 1995) 
and IL-1β (Faustin and Reed, 2008), and it is possible that the inflammation 
associated with UV exposure is required to increase βD3 levels in the skin.  
 
The induction of βD3 following inflammation demonstrates the importance for 
MC1R signaling augmentation in individuals not only with loss of function MC1R 
but specifically with wild-type MC1R. Elevated βD3 levels due to cytokine signaling 
following a sunburn would greatly affect MC1R function because βD3 would 
prevent αMSH activation of MC1R (Swope et al., 2012; Jarrett et al. 2015). UV 
exposure to skin that does not result in sunburn theoretically would induce αMSH 
without a concomitant induction of βD3 and would result in MC1R activation. UV 
exposure that resulted in a sunburn, however, theoretically would lead to the 
induction of both αMSH and βD3 which would compete for binding to MC1R. We 
demonstrated that βD3 expression correlated with TNFα expression (Figure 2.5),  
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therefore, we hypothesize that βD3 induction would positively correlate with the 
degree of sunburn resulting in increased competition for αMSH binding to MC1R. 
Taken together, these data suggest that an individual with wild-type MC1R who 
has sustained a sunburn with inflammation will phenotypically resemble an 
individual with loss-of-function MC1R due to elevated levels of βD3 which will 
compete with and prevent αMSH binding to MC1R. These individuals would have 
a decreased ability to induce eumelanin synthesis and will have similar NER 
kinetics as an individual who has a non-functional MC1R protein emphasizing the 
importance for MC1R signaling augmentation in all individuals. 
 
Although pharmacologic bypass of MC1R regulation would augment MC1R 
signaling in all individuals regardless of their MC1R status or degree of 
inflammation following UV exposure, unregulated MC1R activation would promote 
melanocyte proliferation with the increased potential for malignant transformation. 
Selective induction of eumelanin synthesis and the acceleration of NER without 
the risk of proliferation would be ideal and suggests the importance of 
understanding the interdependence of the three pathways downstream of MC1R. 
All three pathways result from cAMP accumulation and activation of protein kinase 
A (PKA), however, they appear to diverge downstream of PKA (eumelanin 
synthesis – micropthalmia-associated transcription factor (MITF) dependent; NER 
enhancement – ataxia telangiectasia and Rad3 related protein (ATR) dependent; 
proliferation – mechanistic target of rapamycin (mTOR) dependent) suggesting 
they could be independently regulated. One therapeutic possibility would be to 
utilize a combination of pharmacologic drugs to 1) augment MC1R activity and 2) 
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selectively prevent the proliferative response to prevent an increase. In Chapter 4, 
we demonstrated that cAMP induced proliferation is sensitive to rapamycin, an 
inhibitor of mTOR signaling (Figure 4.3, Figure 4.5). We also demonstrated that a 
combination of forskolin (induce MC1R activity) and rapamycin (Figure 5.1) 
functioned as a proof of concept to augment the protective pathways without the 
risk of proliferation as rapamycin treatment did not prevent the induction of 
eumelanin synthesis nor the acceleration of NER downstream of cAMP in vitro 
(Figure 4.4) or in vivo (Figure 4.5 and Figure 4.7). 
 
In Chapter 4, we demonstrated that cAMP signaling led to an increase in mTORC1 
signaling in a PKA dependent manner (Figure 4.1 and Figure 4.2), however, we 
did not specifically determine the mechanism by which cAMP induces mTOR 
function. There are multiple pathways to augment mTORC1 signaling, and we 
hypothesize the mTOR activation immediately following cAMP stimulus occurs in 
a glycogen synthase kinase-3β (GSK3β) dependent manner (Figure 5.2). GSK3β 
acts as an inhibitor of mTORC1 by phosphorylating and activating the mTORC1 
inhibitor complex of tuberous sclerosis 1/tuberin (TSC1/TSC2) (Inoki et al., 2006). 
MC1R activation has been shown to inhibit GSK3β via phosphorylation of GSK3β 
by PKA at Ser9 (Bellei et al., 2011). Inhibition of GSK3β would prevent activation 
of TSC1/TSC2 and result in a disinhibition of mTORC1 signaling. In addition, 
MC1R could lead to mTORC1 activation via elevated MITF levels and sustained 
inhibition of GSK3β via Wnt via an undetermined mechanism (Ploper et al., 2015). 
MITF and Wnt exist in a positive feedback loop as MITF stabilizes Wnt levels  
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Figure 5.1 Pharmacologic Modulation of the MC1R UV Protective 
Pathways 
MC1R signaling activates three distinct pathways downstream of cAMP 
accumulation and PKA activation: 1) the induction of eumelanin 
synthesis via CREB and MITF signaling, 2) the acceleration of nucleotide 
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  synthesis via CREB and MITF signaling, 2) the acceleration of nucleotide 
excision repair (NER) via ATR signaling, and 3) activation of melanocyte 
proliferation via mTOR signaling. A combination of forskolin (an activator 
of adenylyl cyclase) and rapamycin (an inhibitor of mTOR) treatment 
results in the selective activation of the two UV protective pathways 
downstream of cAMP without the risk of melanocyte proliferation. 
Abbreviations: ATR – ataxia telangiectasia mutated and Rad3 related; 
CREB – cAMP responsive binding element; MC1R – melanocortin 1 
receptor; mTOR – mechanistic target of rapamycin; PKA – protein kinase 
A 
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Figure 5.2 Activation of mTORC1 Downstream of cAMP 
MC1R signaling results in the activation of adenylyl cyclase and the 
accumulation of cAMP. cAMP activates PKA which then activates 
mTORC1 signaling and leads to p70S6K phosphorylation of mTOR at 
Ser2448. mTORC1 activation results in melanocyte proliferation. We 
hypothesize that PKA activation of mTORC1 initially occurs downstream 
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  hypothesize that PKA activation of mTORC1 initially occurs downstream 
of GSK3β. PKA phosphorylates GSK3β inhibiting its kinase function. 
GSK3β functions to activate the mTORC1 inhibitors TSC1/TSC2 via 
phosphorylation. Inhibition of GSK3β results in a disinhibition of 
mTORC1 activity. We also hypothesize that elevated MITF levels 
downstream of cAMP result in sustained mTORC1 function. MITF 
stabilizes Wnt levels preventing its degradation, and Wnt can inhibit 
GSK3β kinase function further disinhibiting mTORC1.  
Abbreviations: DEPTOR – DEP domain containing mTOR-interacting 
protein; GSK3β - glycogen synthase kinase 3β; MC1R – melanocortin 1 
receptor; mLST8 – mammalian lethal with sec-13 protein 8; mTOR – 
mechanistic target of rapamycin; mTORC1 - mechanistic target of 
rapamycin complex 1; PKA – protein kinase A; PRAS40 – proline-rich 
Akt substrade 40 kDa; TSC1 – tuberous sclerosis 1; TSC2 – tuberin 
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preventing it from being degraded, and Wnt in turn stabilizes MITF (Rodriguez and 
Setaluri, 2014). Wnt signaling also leads to an inhibition of GSK3β resulting in a 
disinhibition of mTORC1 activation (Inoki et al., 2006). Therefore, immediate 
activation of mTORC1 following cAMP stimulus could result from PKA inhibition of 
GSK3β, and sustained proliferation could result from MC1R induced MITF 
expression and the subsequent stabilization of Wnt by MITF resulting in inhibition 
of GSK3β (Figure 5.2). 
 
The fact that MITF may play a role in MC1R induced proliferation highlights the 
importance of understanding the interaction of the three pathways downstream of 
MC1R as MITF is also important for eumelanin synthesis. In Chapter 3, we 
determined that the interaction between the two protective pathways downstream 
of MC1R appears to be complex and may have a degree of interdependence at 
the level of ATR but not MITF. We demonstrated that MITF was not required for 
ATR dependent acceleration of NER kinetics downstream of MC1R (Figure 3.1 
and 3.2). MITF functions as a global transcription factor and does regulates gene 
expression involved in both eumelanin synthesis (Levy et al., 2006) and NER 
(Strub et al., 2011). MITF induces expression of RPA and POLE (Strub et al., 
2011). Neither protein, however, affects the rate of NER as the rate limiting step of 
NER is at the level of XPA. Because MITF does not regulate XPA gene expression, 
it is not surprising that inhibition of MITF did not affect the kinetics of NER. MC1R 
activation not only increases the kinetics of NER, but also leads to a decrease in 
mutagenesis (Jarrett et al., 2014). Because MITF does promote the expression of 
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genes involved in NER, it is possible that MITF may affect fidelity of NER and 
inhibition of MITF may lead to an increase in mutagenesis independent of kinetics. 
 
ATR is a serine/threonine kinase and functions in response to both replication 
stress and UV induced DNA damage (Cimprich and Cortez, 2008). Our data 
suggest that inhibition of ATR kinase function does not affect PKA phosphorylation 
of cAMP responsive binding element (CREB) (Figure 3.3, 3.5), however, it does 
prevent induction of Mitf and MITF induction of genes involved in eumelanin 
synthesis (Figure 3.6). Thus far, ATR has not been shown to play a role in nuclear 
transcription, however, it does function at the level of DNA to regulate both 
replication stress and the DNA damage response. During situations of replication 
stress and DNA damage, ATR recognizes and binds to a common structural 
theme: sites of single stranded DNA bound with replication protein A (RPA) and 
ATR interacting protein (ATRIP). Evidence suggests that RPA is bound to ssDNA 
in transcription loops (Chaudhuri et al., 2004) suggesting ATR could also have the 
potential to bind to and stabilize the open conformation in transcription as it does 
in both replication stress and NER.  
 
Although our data are consistent with ATR playing a role in global transcription 
regulation, our evidence does not preclude the possibility that ATR directly affects 
MITF function instead. Ataxia telangiectasia mutated (ATM) protein, an additional 
member of the PIKK family and a close relative to ATR, has been shown to directly 
phosphorylate CREB (Shi et al., 2004; Dodson and Tibbetts, 2006) which is 
responsible for the induction of Mitf expression, however, a similar phosphorylation 
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event has not been shown for ATR. To our knowledge, neither ATR nor ATM has 
been shown to directly phosphorylate MITF. The effect of ATR on Mitf transcription, 
therefore, may be due to a direct interaction of ATR and MITF, however, it is highly 
probably that ATR plays an additional role in the cell and affects transcription 
stability by binding to RPA coated ssDNA in transcription loops. 
 
It should be noted that the experiments in Figure 3.3, Figure 3.4, and Figure 3.6 
were conducted following cAMP stimulus alone without UV exposure. We have 
demonstrated that ATR kinase function is activated following UV radiation (Jarrett 
et al., 2014). ATR kinase activity, however, is not dependent upon UV radiation or 
DNA damage as is found in situations of replication stress. Instead, ATR activation 
requires binding of ATR to ATRIP (Cimprich and Cortez, 2008).  Therefore, if 
ATRIP can interact with RPA coated ssDNA in transcription loops, it is possible 
that is sufficient to increase ATR activity. In addition, our studies did not address 
protein changes associated with the pigment genes, and it is possible that ATR 
function may affect transcription but does not affect the pigment protein levels, and 
therefore does not play a role in eumelanin synthesis.  
 
5.2 Limitations 
 
5.2.1 Neonatal Skin Explants 
 
Although we do not anticipate that gender would play a role in MC1R signaling and 
regulation, there is a potential for gender bias in our results in Chapter 2 as all of 
the neonatal skin explants were derived from discarded foreskin tissue and are 
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therefore all from male subjects.  In addition, the foreskins were collected over a 
few months’ time period, and the circumcisions were performed by multiple 
individuals with varying techniques and experience. We cannot exclude that the 
variations in βD3 induction were dependent upon different removal procedures. 
We also predict that the samples were UV naïve, however, because they were de-
identified, it is possible that the infants received light therapy for various medical 
conditions including jaundice prior to circumcision. There are also situations which 
preclude an infant from being circumcised immediately after birth, and samples 
could have come from infants who were past the neonate age. Finally, the skin 
samples were collected daily, however, the time in media prior to processing varied 
from 0-4 hours which could have affected our results.  
 
An alternative approach using skin biopsies collected from individuals undergoing 
plastic surgery (i.e. breast reduction or abdominoplasty) would provide skin 
samples from both males and females. Collecting biopsies from plastic surgery 
would provide skin samples from adults, and it would be difficult to control for 
whether the skin had been exposed to UV radiation. 
 
5.2.2 Primary Human Melanocyte Cell Lines 
 
The primary human melanocyte cell lines utilized were derived from male foreskin 
samples, therefore, our cell culture results in Chapter 3 may have a gender bias 
similar to the neonatal skin explants. In order to control for a gender bias, future 
experiments could be performed in primary human melanocyte cell lines isolated 
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from skin biopsies collected from plastic surgeries as mentioned above which 
could be taken from both males and females. 
 
5.2.3 SK-MEL-2 Transformed Melanoma Cell Line 
 
The biochemistry experiments conducted in Chapter 4 were performed exclusively 
in a transformed melanoma cell line. Transformed malignant cells have altered 
properties and signaling compared to their non-malignant cell counterparts. mTOR 
signaling, specifically, is often altered and upregulated in transformed cells. In 
addition, the experiments revolve around induction of protective pathways to 
prevent melanoma development. The experiments could be repeated in multiple 
transformed melanoma cell lines to ensure that the results were not cell line 
specific. In addition, the experiments would need to be repeated in primary human 
melanocytes to demonstrate that the protective pathways could be induced in 
normal, non-transformed cells.  
  
5.2.4 Murine Model 
 
Melanocytes in non-transgenic mouse skin migrate down through the dermis into 
the hair follicle as the animal develops rather than remaining near the interfollicular 
junction as in human skin. The cKit-SCF transgenic mice with humanized skin 
naturally retain the melanocytes at birth, but after weaning, the melanocytes also 
migrate away from the epidermis. Topical treatment with forskolin results in 
melanocyte retention in the epidermis, however, it is unclear whether the 
melanocytes are dividing or simply not migrating. Therefore, the mice may be an 
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inappropriate model to study melanocyte proliferation and other models such as 
the MH19 murine model which better retains the melanocytes throughout its 
lifetime should be used in future studies. 
 
The NER experiments conducted in the cKit-SCF transgenic mice with mutated 
Mc1r (Mc1r e/e) were done on whole skin biopsies, and the results are therefore 
not melanocyte specific. A majority of cells in skin are of a non-melanocyte origin, 
and therefore, it is not possible to make conclusions specific to melanocyte biology 
utilizing whole skin. 
 
5.3 Future Directions 
 
Future directions will focus on three main goals: 1) better understanding the 
regulation of βD3 following UV radiation, 2) determining the mechanism of cAMP 
induction of mTOR signaling, and 3) translational applications. 
 
5.3.1 βD3 Regulation 
 
Future studies will further clarify the role of UV exposure on the induction of βD3. 
In vivo studies demonstrated that exposure of human skin to UV radiation resulted 
in βD3 mRNA induction (Glaser et al., 2009), however, in Chapter 2, our data 
suggest that UV radiation alone was insufficient for βD3 induction in ex vivo human 
skin explants. We hypothesize that the discrepancy in the results lies in the lack of 
a physiologically intact immune system in the ex vivo explants. A combination of 
cell culture and in vivo human studies would best elucidate whether inflammation 
associated with UV exposure is required for βD3 induction.  
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Primary human keratinocytes could be cultured independently to confirm whether 
UV damage alone causes induction of βD3. In addition, primary human 
keratinocytes could be co-cultured with primary human melanocytes in a transwell 
apparatus prior to UV exposure to determine whether UV induces a factor from 
melanocytes necessary for βD3 induction. We hypothesize that UV treatment 
alone would not induce βD3 expression in vitro due to lack of cytokine induction. 
Although UV treatment has been shown to induce TNFα production in 
keratinocytes (Schwarz et al. 1999; An et al., 2010), the degree of induction may 
not be enough in vitro to induce βD3. 
 
In vivo experiments utilizing UV exposure of human skin would further confirm 
whether the immune system is required. Human skin which is not normally 
exposed to UV radiation (i.e. the buttocks region) would be ideal for experiments. 
Small regions of skin from each individual could be exposed to multiple doses of 
UV to determine whether increased UV exposure correlated with βD3 induction 
and cytokine induction. 
 
Thus far no studies have demonstrated that the murine βD3 homolog functions as 
the human βD3 with respect to MC1R. If experiments could demonstrate that the 
murine βD3 homolog could bind to MC1R and affect its function, it would be 
possible to test whether increased UV exposure would affect βD3 levels and MC1R 
function, specifically accelerated NER kinetics. Mice with a wild-type and mutant 
MC1R protein could be exposed to increasing doses of UV radiation and NER 
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kinetics compared over time. If the murine βD3 can bind to MC1R and prevent 
αMSH from binding to MC1R, we hypothesize that increased exposure of UV 
radiation would result in 1) increased cytokine production, 2) increased βD3 
production, and 3) prevention of αMSH acceleration of NER in mice with a wild-
type MC1R. 
 
5.3.2 cAMP and mTOR Mechanism 
 
In Chapter 4, we demonstrated that mTORC1 was activated following cAMP 
accumulation, however, we did not determine the mechanism by which cAMP 
induced mTORC1 activity. mTOR is regulated via numerous pathways many of 
which converge on the mTORC1 inhibitors TSC1/TSC2 (Laplante and Sabatini, 
2012). Because PKA has been shown to inhibit GSK3β, an activator of 
TSC1/TSC2 (Inoki et al., 2006), we hypothesize that mTORC1 activation 
immediately downstream of MC1R is a result of GSK3β inhibition. We would first 
assess whether cAMP accumulation increased GSK3β phosphorylation at Ser9 in 
a PKA dependent manner. We would next test whether GSK3β dependent 
phosphorylation of TSC2 on Ser1371, Ser1375, Ser1379, and Ser1383 was 
altered downstream of cAMP.  
 
GSK3β function can also be inhibited by Wnt signaling (Inoki et al., 2006). Because 
MITF has been shown to stabilize Wnt levels, we hypothesize that increased MITF 
levels downstream of MC1R activation would stabilize Wnt levels resulting in 
GSK3β inhibition and sustained mTORC1 activation and proliferation. We would 
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first test the duration of mTORC1 activation downstream of MC1R and assess 
GSK3β phosphorylation of TSC1/TSC2. Finally, we directly test the role of MITF in 
sustained mTORC1 activation and determine whether MITF knockout affected 
mTORC1 function and GSK3β phosphorylation of the TSC1/TSC2 complex. 
 
5.3.3 Translational Approach 
 
Chapter 4 demonstrates a proof of concept that it is possible to selectively enhance 
the MC1R protective pathways without the risk of proliferation via a combination of 
pharmacologic drugs. Although topical applications of rapamycin have been used 
therapeutically in disease states including tuberous sclerosis with few 
complications (Wataya-Kaneda et al., 2011), rapamycin is an immunosuppressant 
and there are risk factors associated with using rapamycin for extended periods of 
time including elevated levels of infection and metabolic alterations (Salmon, 
2015). In addition, there are risk factors associated with global increased cAMP 
levels as would be found following treatment with either forskolin or rolipram rather 
than the selective activation of cAMP in melanocytes following treatment with a 
melanocortin analog. cAMP functions as a second messenger in smooth muscle 
cells causing relaxation. Elevated levels of systemic cAMP would result in 
decreased blood pressure from blood vessel dilation and constipation from 
inhibition of peristalsis.  
 
We demonstrated that mice required a minimum of a three-day pre-treatment with 
forskolin prior to UV exposure to see an acceleration of NER. Mouse skin is much 
thinner than human skin, and theoretically, human skin would require a longer 
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duration prior to UV exposure for the drug to absorb to levels necessary to see 
beneficial effects in addition to continued treatment for the duration of UV 
exposure. Therefore, individuals would require prolonged exposure to a 
forskolin/rapamycin treatment with the consequence of elevated global cAMP 
levels and immunosuppression. There are psychosocial components to a 
prolonged treatment regiment, in addition to the side effects, as patient medication 
compliance is a concern (Brown and Bussell, 2011), and patient compliance 
decreases with complexity of medication (Jin et al., 2008). Future studies, 
therefore, could focus on three concepts: 1) identifying melanocyte specific targets 
to augment cAMP such that there is diminished systemic side effects, 2) better 
characterizing MC1R induced proliferation to identify a novel target to inhibit, and 
3) developing a more potent treatment to minimize complexity and maximize 
potential patient compliance. 
 
5.4 Summary 
 
In summary, the overall goal of this dissertation was to better characterize the 
complexities of MC1R signaling, and to specifically assess the interdependence of 
the pigmentation, NER, and proliferation pathways to determine whether they 
could be manipulated in a translationally relevant manner. We have determined 
that βD3 expression is not induced following UV radiation, however, it correlates 
with cytokine induction  (Chapter 2). We have also determined that ATR but not 
MITF may play a role in both eumelanin synthesis and NER (Chapter 3). Finally, 
we demonstrated that cAMP induced proliferation is a result of mTORC1 signaling 
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and demonstrated that selective activation of the UV protective pathways 
downstream of cAMP is possible without the risk of proliferation via a combination 
therapy of forskolin and rapamycin (Chapter 4). 
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APPENDIX A 
 
The author retains copyright of materials published in F1000Research and 
Frontiers in Genetics and by the InTech publishing group. Documents are 
distributed under the Creative Commons Attribution-NonCommercial 4.0 
International which permits users to copy, redistribute, and adapt the material in 
any format. 
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